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CHAPTER I 
GENERAL INTRODUCTION AND 
PROBLEM STATEMENT 
1 
GENERAL INTRODUCTION AND PROBLEM STATEMENT 
Introduction 
The science studying the interactions between drugs and l iv ing 
systems, pharmacology, is conventionally divided into pharmaco­
kinetics and pharmacodynamics. Pharmacokinetics concern absorption, 
d i s t r i b u t i o n , biotransformation and excretion of a drug, and 
pharmacodynamics concern the effects or so-called pharmacological 
actions, be i t therapeutic or tox ic, of a drug. Useful drugs can 
produce powerful effects on l iv ing beings. Within the context of 
pharmacotherapy these effects are modified by factors which ensue 
from patient character ist ics, e.g. i r r e v e r s i b i l i t y of lesions, and 
alterations in drug handling. 
Clinical pharmacology comprises the s c i e n t i f i c approach to the 
application of drugs with a proven or an expected therapeutic value 
in man. 
Drug pharmacokinetics in patients need not correspond with data 
obtained in healthy young volunteers. Patients may share demographic 
or c l i n i c a l characteristics that change drug disposition.Obviously, 
altered pharmacokinetics in a particular subgroup of patients can 
have serious consequences, e.g. the unforeseen occurrence of ( lethal) 
adverse drug reactions in geriatr ic patients due to benoxaprofen 
accumulation!. Pharmacotherapy in the elderly often requires 
precautions in view of age-related changes in body composition, 
hepatic and kidney functions2. Especially regarding diminished 
renal function, there are many examples of altered drug pharmaco-
kinet ics^. Alterations of drug disposition may exist in other 
patients due to hampered metabolism in hepatic disease4, or due to 
hypo al bumiηaemi a in the case of a highly albumin-bound drug5. 
Inflammatory diseases are associated with changes of a regulatory or 
an adaptive kind in organs and body f l u i d s of patients, and these 
changes may influence the handling of drugs. Non-steroidal ant i-
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inflammatory drugs (NSAID) are applied in the symptomatic treatment 
of inflammatory j o i n t diseases. These studies concerned the possible 
effects of the disease ac t iv i ty of rheumatoid a r t h r i t i s and of 
patient age on naproxen pharmacokinetics. Furthermore, two side 
effects of NSAID were studied also in relat ion with age and disease 
ac t i v i t y : one well-known (gastrointestinal blood loss) and one 
suspected (congestive heart fa i lure) side ef fect . 
Choice of drug: naproxen 
Naproxen [(+)-6-methoxy-a-methyl-2-naphthaleneacetic ac1d]6 belongs 
to the group of 2-aryl propionic acid NSAID. The analgesic and ant i -
inflammatory properties of NSAID make these drugs the f i r s t choice in 
the pharmacotherapy of inflammatory locomotor diseases, with special 
emphasis on rheumatoid a r th r i t i s . The most probable mode of action of 
NSAID is by interference with prostaglandin synthesis at the si te of 
inflanimation?,8# The wealth of d i f ferent NSAID available, without 
one proven superior drug, forces the prudent c l in ic ian to select a 
small number as tools to work with^. 
In chronic a r t h r i t i s , anti-inflammatory therapy can be achieved with 
either 50 mg diclofenac sodium three times da i ly , 500 mg naproxen 
twice da i l y , 20 mg Piroxicam once da i l y , or another NSAID in 
appropriate doses. The most important factor in the selection of the 
r ight drug for the r ight patient is the individual va r i ab i l i t y in 
response to d i f ferent NSAID. A twice dai ly dosage regimen is 
convenient to the patient and may have the advantage that night pain 
and morning st i f fness are covered in patients taking the second dose 
late in the evening. Naproxen is an often prescribed NSAID in the 
pharmacotherapy of a r t h r i t i s ^ , ! ! . 
From a pharmacological point of view i t is important to note that the 
2-aryl propionic acid NSAID, including naproxen, have a centre of 
asymmetry, raising two enantiomers with a mirror immage relat ionship. 
The two chiral forms d i f fe r in anti-inflammatory ac t iv i t y and in rate 
of metabolism. Chiral inversion of the inactive to the active 
enantiomer further complicates th is matter, since pharmaceutical 
formulations of 2-aryl propionic acids NDAID, save naproxen, contain 
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a racemic mix tu re^ . Naproxen formulations contain only the active 
( + ) enantiorner. Pharmacokinetic studies of racemates, being mixtures 
of two or more pharmacologically active compounds, without an attempt 
to separate the contribution of the individual stereoisomers or even 
without a notice on the very phenomenon, are dissuaded^. 
Earl ier studies suggested that naproxen-albumin binding is an 
important determinant of naproxen pharmacokinetics^.In volunteers, 
the intake of increasing doses of naproxen did not lead to a linear 
growth of the area under the concentration-time curve (AUC).Non-
l inear, decreasing increments of AUC have been observed upon 
administration of increasing doseslS.lö, probably due to increased 
clearance of the drug resulting from saturation of protein binding. 
For the study of the consequences of naproxen-albumin binding, 
measurements of protein-unbound drug concentrations are necessary. 
Choice of disease: rheumatoid a r th r i t i s 
Rheumatoid a r th r i t i s is defined by the c r i t e r i a of the American 
Rheunatism Associat ion^. ¡n patients with rheumatoid j o in t 
inflammation, the indication for long-term treatment with one of the 
NSAID is evident. The disease runs a chronic, f luctuat ing course, 
with active periods of polyarticular inflammation relieved by periods 
of remission. The disease act iv i ty of rheumatoid a r th r i t i s has a 
variable expression in individual patients and can be assessed on the 
basis of c l in ica l and biochemical f ind ings^,19, Relevant c l in ica l 
findings include a count of the number of swollen, tender and painful 
j o i n t s , estimation of the duration of morning st i f fness and a search 
for extra-art icular manifestations of the disease. Laboratory 
findings comprise the erythrocyte sedimentation ra te , haemoglobin 
concentration and C-reactive protein. In relat ion with naproxen 
pharmacokinetics i t is of importance to note that active disease is 
associated with hypoalbuminaemia 20,21# The change from active 
disease to remission in a patient within a certain period of time 
allows the investigator to study naproxen pharmacokinetics separately 
in these two conditions in one patient. Patients with classic 
rheumatoid a r t h r i t i s in a period of active polyart icular inflammation 
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were therefore selected for this study. 
Active or progressive jo in t inflammation warrants, apart from NSAID 
therapy, treatment with a remission-indue ing agent, i .e . hydroxy-
chloroquine, aurothioglucose or d-penicillamine. Individualization of 
pharmacotherapy is required, and in the study population of patients 
with active rheumatoid a r th r i t i s co-medication could therefore not be 
standardized. Interference of such and other co-medication with 
naproxen pharmacokinetics could not be excluded completely, but i t 
was avoided where possible. 
PROBLEM STATEMENTS 
Naproxen pharmacokinetics in patients with rheumatoid a r t h r i t i s 
during active polyart icular inflammation (Chapter I I ) 
Naproxen pharmacokinetics in healthy volunteers are well-known22. 
Differences exist between young healthy volunteers and patients with 
rheumatoid a r t h r i t i s : e.g. age, the preponderance of women with 
a r th r i t i s and the presence of a generalized inflammation. These may 
contribute to alterations in naproxen pharmacokinetics in patients. 
I t was expected that the lower serum albumin concentration in 
patients would influence the volume of d is t r ibut ion and tota l body 
clearance of the highly albumin-bound drug by exceeding the binding 
capacity at a lower serum naproxen concentration. Changes in 
clearance of protein-unbound drug might re f lec t the influences of 
disease ac t iv i ty on drug metabolism and were therefore studied by 
measurements of unbound naproxen concentrations. A pharmacokinetic 
study was performed in 8 patients with active polyart icular 
inflammation of rheumatoid a r th r i t i s and 8 healthy young male 
volunteers, during chronic treatment with oral naproxen 500 mg twice 
dai ly . 
Naproxen pharmacokinetics in elderly patients (Chapter I I I ) 
Data on naproxen pharmacokinetics in young and elderly healthy male 
volunteers during chronic intake of 375 mg naproxen twice dai ly have 
been publ ished^. A 50% reduction of the protein-unbound drug 
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clearance was found, together with a doubling of the unbound drug 
fraction; the latter pointing to diminished serin albunin binding. 
This resulted in total drug concentrations and total body clearances 
of naproxen which were indistinguishable from those in the young. 
Another study compared naproxen pharmacokinetics in elderly patients 
with results in middle-aged patients^. We performed a study of 
naproxen pharmacokinetics in male and female elderly patients with 
500 mg oral naproxen twice daily and compared the results with data 
obtained in young healthy volunteers. Our study adds further data to 
current knowledge, because it compares elderly patients with healthy 
young volunteers after multiple high dosages. 
Disease activity of rheumatoid arthritis and naproxen pharmaco­
kinetics; a within-patient study (Chapter IV and V) 
A within-patient study was performed on naproxen pharmacokinetics in 
rheumatoid arthritis at the time of active polyarticular inflammation 
compared with a period of major improvement in disease activity. A 
total of 16 potential subjects entered the study during the period 
from December 1984 to July 1986. Ten of these attained major 
improvement, nearly or completely fulfilling the criteria of complete 
remission^ in rheumatoid arthritis at some time during the study 
period until January 1987. Of the ten eligible patients, two refused 
cooperation with a second investigation of naproxen pharmacokinetics. 
Both gave a similar reason for their refusal, no longer feeling the 
need for NSAID medication at a rather high dosage. One other patient 
did not comply with the protocol. In one patient acenocoumarol 
therapy had been started some time after the first investigation; 
this prevented a second study. Thus six patients ranained, in whom 
the study was completed. One of these six is described separately 
(Chapter V). 
Gastrointestinal blood loss during treatment with naproxen for 
rheumatoid arthritis (Chapter VI) 
Recent studies show both a significant risk of upper gastrointestinal 
tract bleeding associated with NSAIO exposure in the population^ 
б 
and a significantly more frequent use of NSAID in those admitted to 
hospital with a bleeding peptic ulcer27. NSAID damage the gastro-
intestinal tract mucosa at least partly as a consequence of 
inhibition of local prostaglandin synthesis^. Subjective s>mptoms 
do not correlate with the presence of endoscopic lesions^ and 
abdominal pain is an infrequent presenting complaint of gastro-
intestinal bleeding due to NSAID^O. A quantitative estimate of the 
daily faecal blood loss can be obtained by the method of reinfused 
51cr-labelled autologous erythrocytes. We studied gastrointestinal 
blood loss in 9 patients with active rheumatoid arthritis on chronic, 
well-tolerated therapy with 500 mg oral naproxen twice daily to look 
for a possible correlation with total or unbound drug concentrations 
or the degree of disease activity. 
Congestive heart failure due to non-steroidal anti-inflammatory drugs 
in the elderly (Chapter VII) 
NSAID in common use today can be the cause of solute retention·^. 
Furthermore, NSAID may attenuate the effects of diuretics·^. The 
possibility of inducing congestive heart failure by instituting NSAID 
therapy in the aged, therefore, merits attention. Chapter VII 
describes the results of an attempt to assess the probability of this 
suspected adverse drug reaction. Data were collected by means of a 
questionnaire to practicing physicians, participants of a post-
graduate course on locomotor diseases in the elderly, and by analysis 
of the medical records of 600 patients with congestive heart failure 
in the Department of Medicine at the University Hospital St Radboud. 
This approach was based on the supposition that frequent occurrence 
of the presumed side effect should make it possible to locate at 
least some evident cases by inquiry, or within a number of 600 
available patients with congestive heart failure. The results of this 
study are presented in Chapter VII. 
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CHAPTER I I 
NAPROXEN PHARMACOKINETICS IN PATIENTS WITH RHEUMATOID 
ARTHRITIS DURING ACTIVE POLYARTICULAR INFLAMMATION 
FA van den Ouwel and, MJAM Franssen, LBA van de Putte, 
Y Tan, CAM van Ginneken and FWJ Gribnau 
Br J cl in Pharmacol 1987; 23: 189-193 
(with permission of the editor) 
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Br J dm Pharmac (1987). 23, 189-193 
Naproxen pharmacokinetics in patients with rheumatoid 
arthritis during active polyarticular inflammation 
F A VAN DEN OUWELAND1 '. M J A M FRANSSEN '. L. В A VAN DE PUTTE '. Y TAN ' 
C A M VAN GINNEKEN'& F W J GRIBNAU :; ' 
1
 Division of Rheumatology, and : Division of General Internal Medicine, Department of Medicine University 
Hospital of St Radboud, and ' Division of Clinical Pharmacology and Pharmacokinetics, Institute of Pharma­
cology, University of Nijmegen, Nijmegen. The Netherlands 
1 Patients with rheumatoid arthritis often have hypoalbuminaemia as a sign of disease 
activity. In view of the extensive binding of naproxen to albumin, the pharmacokinetics of 
total and unbound drug were studied in eight patients and eight healthy male volunteers 
during chronic intake of 500 mg twice daily. 
2 The area under the serum concentration-time curve of total naproxen during a dose 
interval, AUC (0,12), was smaller in patients (641 ± 101 mg Г 1 h) than m volunteers (896 
± 85 mg Г 1 h; Ρ < 0.0001). The unbound naproxen AUCu (0,12) was larger in patients 
(1.9 ± 0.9 mg Г ' h) than in volunteers (0.7 ± 0.2 mg Г 1 h; Ρ < 0.01). 
3 The higher unbound naproxen concentrations in patients were accompanied by an 
approxmately 40% increase in apparent clearance/bioavailability {CUF) and a 60% 
increase in volume of distribution (VIF). 
4 Both CL/F and VIF were inversely correlated with the individual serum albumin 
concentration (r =-0.76, Ρ < 0.001; r = -0.85, Ρ < 0.001, respectively) 
5 The high unbound naproxen concentration in the serum of patients with active rheumatoid 
arthritis and concomitant hypoalbuminaemia is not known to be accompanied by an 
increase in side effects and may be beneficial if anti-inflammatory effects correlate with 
unbound drug concentration. 
Keywords clinical pharmacokinetics naproxen rheumatoid arthritis 
hypoalbuminaemia 
Introduction 
In patients with active rheumatoid arthritis arthritis in an active phase of the disease, and 
general signs of inflammation are often present, compared the results with values obtained in 
one of the features being a low serum albumin eight healthy male volunteers. 
concentration (Baum & Ziff, 1985) The pharma­
cokinetics of highly albumin bound drugs, such 
as naproxen, can be expected to differ from Methods 
normal in patients with hypoalbuminaemia 
(Koch-Weser & Sellers, 1976; Rowland, 1984). Eight in-patients, aged 62 ± 3 years (mean ± 
Therefore we studied naproxen pharmacokinetics s.d ), with either classical or definite rheumatoid 
during chronic therapy at a dosage of 500 mg anhntis according to the entena of the Amencan 
twice daily in eight patients with rheumatoid Rheumatism Association (Ropes et al., 1958), 
Correspondence Dr F A Van Den Ouweland, Department of Mediane, Division of Clinical Pharmacology, 
University Hospital St Radboud, Ρ О Box 9101. 6500 HB Nijmegen. The Netherlands 
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F. Α. Van Den Ouweland et al. 
entered the study. The individual values of clinical 
and laboratory parameters to assess disease activity 
in each patient and medication data are shown in 
Table 1. All patients had been taking naproxen 
500 mg twice daily (Naprosyne®. tabi. 250 mg. 
Sarva-Syntex Nederland, Rijswijk. The Nether­
lands) for at least 14 days before the study. On 
the day of study the morning dose of any medi­
cation other than naproxen was either omitted 
or postponed until noon. Naproxen 500 mg was 
given with breakfast. Immediately before 
ingestion of the drug an indwelling catheter was 
placed in an antecubital vein and a sample of 
blood was drawn at time ίο- Further samples 
were taken 0.5.1,1.5,2,3,4,8, and 12 h after i„. 
During this period the freely voided urine was 
collected. The mean endogenous creatinine clear­
ance was 85 ± 22 ml min - 1; a normal value for 
the age of the patients (Siersbaek Nielsen et al., 
1971). The mean serum albumin concentration 
was 28 ± 2 g I - 1 . This was measured by the 
bromocresolgreen method according to Doumas 
et al (1971). Serum and urine samples were 
stored at -20° С until analysis. 
Eight healthy male volunteers, aged 24 ± 3 
years, with a mean serum albumin concentration 
of 45 ± 2 g I - ' , entered the study. They had not 
taken any drug during at least 1 month preceding 
the study and no drug intake other than naproxen 
was allowed. 
Naproxen 500 mg was administered twice daily 
at 08.30 h and 20.30 h. The morning dose of the 
drug was taken with breakfast. On the fourth 
day of naproxen intake blood samples were taken 
and unne collected, as described for the patients. 
Measurement of naproxen in samples of serum 
and urine was by high pressure liquid chromato­
graphy and spectrofluorophotometric detection: 
the coefficient of variation for total serum 
naproxen (concentration range 20 - 120 mg Г ') 
was 1.2% (Van Loenhout et ai. 1982). The 
unbound naproxen serum concentration in the 
samples was determined after equilibrium dialy­
sis at 37° С for 5.5 h against isotonic Sorensen 
phosphate buffered saline, pH 7.4. The dialysis 
cell contained 1 ml serum and 1 ml buffer, sepa­
rated by a cellulose dialysis membrane (Cupro-
phane M150). Adsorption of the drug to the 
membrane was negligible. The coefficient of 
variation over the concentration range 0.03-0.3 
mg I"1 was 4.2%. The area under the concen­
tration-time curve during a dose interval of 12 h, 
AUC (0,12), was estimated using the linear 
trapezoidal rule. Total body clearance/bioavaiia-
bility (CUF) was calculated as: dose (500 mg)/ 
AUC (0,12) and expressed in ml mm"1 or 1 
min - 1. The elimination rate constant (λ) was 
obtained from the slope of the log-linear regres­
sion line through the last three time points in the 
dose interval. The elimination half-life <
й
 was 
calculated from λ- 1-0.693. An apparent volume 
of distribution (VIF), corrected for individual 
body weight, was calculated from C\JF\~l 
divided by the individual body weight From the 
values of unbound serum naproxen concentrations 
identical calculations were performed to obtain 
the pharmacokinetic parameters for unbound 
naproxen: AUCu (0,12), CLu/F, /*u and Vu/F. 
Statistical analysis 
The means of the pharmacokinetic parameters 
in both groups were analysed for statistically 
significant differences with the two tailed (-test 
Table 1 Measures of disease activity and drug therapy in eight patients with active 
rheumatoid arthrms during chronic therapy with naproxen 500 mg twice daily 
Patients 
Age 
<\ ears) 
60 
64 
63 
65 
55 
63 
65 
61 
Sex 
F 
F 
M 
M 
F 
F 
F 
F 
Hgb' 
(gm 
8 5 
9 7 
9 8 
11 1 
11.0 
9 9 
9 9 
8 5 
ESRt 
(mm h-') 
113 
129 
88 
116 
56 
77 
80 
80 
Morning 
stiffness 
(hl 
1 
0.5 
0 
I 
1 5 
0 
2 
2.5 
Number of 
swollen 
joints 
25 
17 
7 
10 
13 
9 
9 
28 
Number of 
tender 
joints 
4 
10 
7 
17 
6 
9 
5 
30 
Comedicationt 
1.2 
1.3 
1.3 
1.4 5 6. 
1.5.7 
1.5 
8 
8.9 
' Hgb haemoglobin normal \alues M 14-18 g/dl: F 12-16 g/dl 
ESR ervlhrocvte sçdimeniation rate (Westergrcn) normal \alue F < 21 mm h -1: 
M < lO'mmlT1 
Comedicanon 1 aurolhioglucose, 2 oxazepam. 3 Cimetidine. 4. alprenolol. 
5 ferrous fumarate. 6 temazepam. 7 frusemide. 8 azathiopnne. 9 prednisone. 
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Naproxen pharmacokinetics in rheumatoid arthritis 
for unpaired data Results were expressed as 
mean ± s d unless otherwise stated 
Study ethics 
The study was approved by the ethics committee 
of the University Hospital St Radboud Patients 
gave verbal and volunteers written informed 
consent 
Results 
The pharmacokinetic data of naproxen during 
chronic intake of 500 mg twice daily both for 
patients with active rheumatoid arthntis and the 
healthy male volunteers are listed in Table 2 
The mean total and unbound serum naproxen 
concentration-time curves for patients with active 
rheumatoid arthntis and healthy male volunteers 
are shown in Figure 1 The serum naproxen 
concentrations at time 0 (C
m
,„) and peak ( C
m a l ) 
were significantly lower in patients than in healthy 
volunteers (both Ρ < 0 0001), also the AUC 
(0,12) was smaller in patients 641 ± 101 mg 1"'h 
w896 ± 85 mg 1 - ' h (ƒ>< 0 0001) In (he patient 
group there was a significantly larger W a n d CU 
F. whereas t^ was not different from that in the 
group of healthy volunteers The unbound nap­
roxen concentrations at C
m
,
n
 and C
m a
, were sig­
nificantly higher in patients than in healthy 
volunteers (P < 0 02 and Ж 0 01 respectively), 
also the AUCu (0,12) was found to be greater 1 9 
± 0 9 mg Г ' h vsO 7 ± 0 2 mg Г ' h (Ρ < 0 01) 
The values of CLu/f and Vu/F were significantly 
smaller in patients with active disease than in 
volunteers (both Ρ < 0 001). 
The values of VIF in both groups were nega­
tively correlated with serum albumin concentration 
Table 2 Pharmacokinetics (mean ± s d ) of naproxen in eight patients with active rheumatoid 
arthritis and eight healthy male volunteers during chronic intake of naproxen 500 mg twice daily 
^-mjx 
C-min 
AUC (0.12) 
CUF 
VIF 
'ν 
(mg I 
(mgl 
(mg Г 1 
(ml min 
(1 min" 
(Ikg-
(h) 
') 
') 
h) 
"') 
') 
') 
Total 
Patients 
79 + 12 
38 + 8 
641 + 101 
13 3 ± 2 5 
0 18 ± 0 03 
10 4 + 2 0 
serum naproxen 
Volunteers 
ПО ± 7 
57 ± 7 
896 ± 85 
9 4 ± 0 9 
0 11 ± 0 01 
10 0 ± 1 8 
Ρ 
< 0 0001 
< 0 0001 
< 0 0001 
< 0 001 
< 0 0001 
NS 
Unbound serum naproxen 
Patients 
0 42 ± 0 21 
0 07 ± 0 02 
1 9 ± 0 9 
5 3 ± 2 5 
26 ± 13 
3 6 ± 0 8 
Volunteers Ρ 
0 19 ± 0 07 < 0 02 
0 03 ± 0 01 < 0 01 
0 7 ± 0 2 < 0 01 
1 1 9 ± 2 7 < 0 001 
72 ± 27 < 0 001 
4 8 ± 0 8 < 0 02 
— 0 20 
8 10 12 
Time (h) 
Figure 1 Serum naproxen concentration-time curves in eight patients with active rheumatoid arthntis ( · ) 
and eight healthy male volunteers (o) for total (a) and unbound drug (b) over one dose interval during 
chronic intake of 500 mg naproxen twice daily Bars indicate the s e mean 
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(r= - О ^ . Ж О О О І ) The values of CL/Fin both 
groups were also inversely correlated with serum 
albumin concentration (r = - 0 76, Ρ < 0 001) 
The recovery of naproxen and desmethyl-
naproxen conjugates, excreted in the unne dunng 
the 12 h dose interval was similar in the patients 
and the volunteers (1 2 ± 0 2 mmol and 1 3 ± 
0 1 mmol naproxen equivalents, respectively) 
These values represented 54% and 59% of the 
oral naproxen dose dunng chronic intake in 
patients and volunteers, respectively 
Discussion 
In the group of eight patients with active rheu­
matoid arthritis the value of AUC (0,12) was 
72% that in eight healthy male volunteers dunng 
one dose interval of 12 h on chronic treatment 
with naproxen 500 mg twice daily All subjects 
took the morning dose of 500 mg with breakfast, 
which is known not to interfere with the com­
pleteness of drug absorption (Segre, 1975) Any 
other medication in the patient group was either 
omitted or given at a later time to avoid a possible 
interaction with naproxen absorption In healthy 
volunteers naproxen absorption after oral admin­
istration of a single dose up to 4000 mg is nearly 
complete However, non-linear, decreasing in­
crements of AUC have been observed upon 
administration of subsequent larger doses, 
probably due to saturation of albumin binding 
(Runkel era/, 1974, 1976) 
The similar renal excretion of drug equivalents 
in patients and volunteers in this study suggests 
an unchanged absorption of the drug in patients. 
For these reasons it is concluded that the smaller 
AUC (0,12) values in patients with rheumatoid 
arthritis were not the consequence of impaired 
absorption of naproxen in active disease 
The alterations of AUC (0,12), VIF and CUF 
found in patients with active rheumatoid arthritis 
dunng chronic naproxen treatment are consistent 
with the pharmacokinetics of comparable com­
pounds The clearance of drugs with high albumin 
binding and a low extraction ratio is affected by 
changes in the unbound drug fraction, and an 
increase in the concentration of unbound drug 
thus results in a higher total clearance (Rowland. 
1984) Both VIF and CUF in the patients with 
active disease were 40-60% higher than the cor-
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CHAPTER III 
PHARMACOKINETICS OF HIGH-DOSAGE 
NAPROXEN IN ELDERLY PATIENTS 
FA van den Ouwel and, PAF Jansen, Y Tan, LBA van de Putte, 
CAM van Ginneken and FWJ Gribnau 
(submitted for publication) 
17 
SUMMARY 
- AFter mult iple oral doses of 500 mg naproxen twice da i ly , eight 
young healthy male volunteers and six male and female elderly 
patients participated in a pharmacokinetic study. 
- Serum naproxen levels were measured by high-pressure l iquid 
chromatography; protein-unbound drug was determined after 
equi l ibr i im d ia lys is . 
- A s ign i f icant ly lower maximal serum concentration (Cpea|<), 
smaller area under the curve during one dose interval [AUC(0-12)J, 
larger total body clearance (CL/F) and apparent volume of 
d is t r ibut ion (V/F.Body Weight-1) were found for the total drug in 
elderly patients. 
- The pharmacokinetics of the protein-unbound drug showed higher 
trough and peak concentrations, larger AUC(0-12)U, and smaller 
(CL/F)U and (V/F)u in the elderly patients. 
- The unbound fract ion (<1% of to ta l naproxen) showed concentration 
dependency; in the elderly a larger unbound fract ion was found. 
- Pharmacokinetic differences between the elderly and the young may 
be explained by a lower serum albumin concentration in the aged, 
together with a decrement in binding a f f i n i t y of naproxen to 
albumin; moreover, the clearance of unbound drug was s igni f icant ly 
reduced in the elderly (281 ± % 1/h) as compared with the young 
(713 ± 164 1/h). 
-We conclude that age-related factors increase serum unbound 
naproxen concentrations. I t is therefore advisable to start 
treatment with naproxen in the elderly at a low dosage. 
INTRODUCTION 
Non-steroidal anti-inflammatory drugs (NSAID) are frequently 
prescribed in rheumatoid a r th r i t i s and osteoar thr i t is . Some NSAID 
have long been available and tend to be given in larger doses even in 
the treatment of elderly patients. I t is therefore important to study 
the pharmacokinetics of NSAID in the elderly during long-term 
administration of r e a l i s t i c , i .e . large doses as used today. We 
performed a pharmacokinetic mult iple dose study with 500 mg oral 
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naproxen twice daily in elderly patients and compared the results 
with those obtained in young healthy volunteers. 
METHODS 
Six elderly male (n~2) and female (n=4) patients were studied. Eight 
young male volunteers, found healthy at examination and not taking 
medication in the preceding month, were given 500 mg naproxen twice 
daily for four days in the form of tablets of 250 mg (NaprosyneR, 
Sarva Syntex Nederland, Ri jswi jk, The Netherlands). The patients had 
been treated with 500 mq naproxen twice dai ly in identical tablets 
for at least two weeks, in view of osteoarthr i t is (n=4) or rheumatoid 
a r t h r i t i s (n=2). Characteristics of the groups are l i s t e d in Table I . 
TABLE I. CHARACTERISTICS OF YOUNG VOLUNTEERS 
AND ELDERLY PATIENTS (mean ± SD) 
age 
height 
weight 
serαπ c r e a t i n i n e 
c r e a t i n i n e clearance 
serum al b i n i η 
(years) 
(cm) 
(kg) 
(Mmol/l) 
(ml/min) 
(g/D 
YOUNG 
(n=8) 
24 ± 2.5 
185 ± 9 
71 ± 11 
83 ± 11 
135 ± 12 
45 t 2 
ELDERLY 
(n=6) 
73 ± 2 . 9 
165 t 6 
60 t 13 
71 ± 10 
66 t 18 
34 + 5 
Ρ 
<0.001 
<0.001 
NS 
NS 
<0.001 
<0.001 
Kidney function was estimated in volunteers by determination of 
endogenous creatinine clearance from 24 hour urinary excretion and 
serum concentration; and in the elderly patients by means of a 
nomogram using the variables age, body weight, gender and serum 
creatinine concentration (Siersbaeck-Nielsen et a l . , 1971). Serum 
albumin concentration was measured by the bromocresolgreen method 
according to Doumas et a l . (1971); reference value: 37-47 g/1. The 
serum albumin concentration in the elderly was s ign i f icant ly lower 
19 
than that in the young (p<0.001) and ranged from 28 to 42 g/1. 
Hypo al bum i η аетп' a in elderly patients was not caused by hepatic 
f a i l u r e , proteinur ia, malnutrit ion or enteropathy. 
In the aged, co-medication was not discontinued: i t comprised 10 mg 
prednisone and 75 mg azathioprine in one pat ient, 400 mg hydroxy­
chloroquine sulphate in one patient and 40 mg furosemide in one 
patient. On the day of study the co-medication was administered at 
least two hours after ingestion of naproxen. For volunteers no drug 
intake other than naproxen was allowed during the study period. On 
the day of study al l subjects received 500 mg naproxen oral ly with 
breakfast after an overnight fast. 
Study design 
Before ingestion of the drug (time 0 ) , and 0.5, 1, 1.5, 2, 3, 4, 8 
and 12 hours thereafter, blood samples were collected from a forearm 
vein. In the patients the sampling points 1.5 and 3 hours post-dose 
were omitted. Serum was separated from cel ls and stored at -2CPC 
u n t i l assay. Total serum naproxen was measured by high-pressure 
l iquid chromatography and fluorophotometric detection (Van Loenhout 
et a l . , 1982). Serum unbound naproxen measurements were performed 
after equilibrium dialysis during 5.5 hours at ЗТ'С against phosphate 
buffered saline. 
Pharmacokinetic analysis 
The area under the serum drug concentration-time curve AUC(0-12) was 
estimated according to the linear trapezoidal rule during one dose 
interval of 12 hours. Total body clearance (CL/F) was calculated as 
dose (500 mg) divided by AUC(0-12). The elimination h a l f - l i f e of the 
drug ( t l / 2 ) was derived from the l ine f i t by least squares to the 
last three log concentration-time points: 4, 8 and 12 hours post-
dose. An apparent volume of d ist r ibut ion (V/F) was calculated from 
the product of clearance and h a l f - l i f e divided by 0.693; also, V/F 
was divided by the body weight to f ind V/F.BW~1. CQ is the serum 
naproxen concentration at time 0, immediately before ingestion of the 
drug; Cpeg^ is defined by the individual 's highest measured 
concentration. 
Pharmacokinetic parameters concerning protein-unbound naproxen were 
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calculated as for total naproxen. Naproxen binding a f f i n i t y to 
albumin and the number of binding sites was estimated with the aid of 
a Scatchard plot (Scatchard, 1949). In converting g/1 to mmol/1 
albumin, a molecular weight of 69,000 was used. 
Stat is t ica l comparisons between groups were made by independent-
sample t - t e s t i n g . 
Volunteers gave written and patients verbal informed consent; the 
study was approved by the University Hospital Ethics Committee. 
RESULTS 
Total and unbound serum naproxen concentrations of young volunteers 
and elderly patients are shown in Figure 1; Table I I gives the 
pharmacokinetic data. 
SERUM TOTAL NAPROXEN (mg/L) 
120-
100 
8 0 -
6 0 -
4 0 -
- 1 — ι — ι — г 
0 2 
π — ι — ι — ι — ι — ι — 
6 8 10 
τ — г 
12 
SERUM UNBOUND NAPROXEN (mg/L) 
0.40 η 
0.20 
0.10 Η 
0.08 
0.06 Η 
0.04 
0.02 -
π I I I 1 Ι Ι г - τ — ι — ι — ι — r 
8 10 12 
TIME (hours) 
FIGURE 1. 
Total ( l e f t panel) and unbound (r ight panel) naproxen serum 
concentration in 8 healthy young (o) and 6 elderly patients ( · ) 
during one dose interval of 500 mq oral naproxen twice dai ly . Bars 
indicate the standard error of the mean. 
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TABLE II. PHARMACOKINETIC DATA (mean ± SD) ON 500 mg ORAL NAPROXEN 
TWICE DAILY IN YOUNG VOLUNTEERS AND ELDERLY PATIENTS 
TOTAL NAPROXEN 
CO 
Cpeak 
AUC(0-12) 
CL/F 
V/F 
V/F'BW-1 
t% 
(mg/!) 
(mg/l) 
(mg/l.h-1) 
(1/h) 
(D 
(i/kg) 
(h) 
YOUNG 
(n-8) 
57 ± 7 
110 t 7 
896 t 85 
0.56 t 0.05 
8.1 t 1.3 
0.11 i 0.01 
10.0 ± 1.8 
ELDERLY 
(n=6) 
48 ± 11 
88 t 9 
694 i 139 
0.75 t 0.15 
10.4 t 4.7 
0.17 t 0.06 
9.3 t 2.3 
Ρ 
NS 
<0.001 
<D.01 
<0.01 
NS 
<0.001 
NS 
UNBOUND NAPROXEN 
(Co)u (mg/D 
(Cpeak)u ^^) 
AUC(0-12)U (mg/l .h- 1 ) 
(CL/F)U (1/h) 
(V/F)
u
 (1) 
(V/F)
u
.BW-l)(l/kg) 
(t%)u (h) 
0.03 ± 0.01 
0.19 ± 0.07 
0.74 t 0.20 
713 ± 164 
5025 t 1634 
72 t 27 
4.8 ± 0.8 
0.09 t 0.02 
0.41 ± 0.23 
1.95 t 0.60 
281 t 96 
1844 t 1125 
30 ± 16 
4.4 + 2.0 
<0.001 
<0.05 
<0.001 
<0.001 
<0.01 
<0.01 
NS 
Statistically significant differences were found for Ср
е а
к^ lower 
in the elderly, AUC(0-12): smaller in the elderly, CL/F: larger in 
the elderly, and V/F.BW"^·: larger in the elderly. Furthermore, 
differences were found in protein-unbound naproxen pharmacokinetics: 
a significantly higher value of the unbound naproxen concentrations 
(Co)u and (Cp
ea
k)u. larger AUC(0-12)U and smaller (CL/F) U 
in elderly patients. (V/F)
u
 and (V/F)U«BW-1 were smaller in the 
elderly as compared with the young volunteers. Naproxen tl/2 and 
( t l / 2 ) u were equal in both groups. 
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UNBOUND NAPROXEN FRACTION 
00025 
00020 
00015 
00010 
00005 
40 60 Θ0 100 
TOTAL SERUM NAPROXEN (mg/U 
FIGURE 2. 
Protein-unbound naproxen fract ion versus tota l serum naproxen 
concentration in one representative young volunteer (o) and one 
elderly patient ( t ) . Assiming a l inear correlation over the 
concentration range of tota l serum naproxen, the equation of the 
least squares regression l ine for the young subject i s : 
Y = 1.3xlO-5X - 2.2x10-4 with a correlat ion coeff ic ient r=0.88 
and for the elderly subject: 
Y = 3.2xlO-5X-7.9xlO-4, with r=0.92. 
The protein-unbound fraction increased with higher total serum 
naproxen concentrations; in the elderly it was more pronounced than 
in young healthy volunteers. This is shown in Figure 2 for one 
representative subject of either group. 
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UNBOUND NAPROXEN ( L ^ M O L ) 
4.0-
3.0-
2.0 
1.0 
1 : 1 1 1 
0.2 0 4 0 6 0 8 1.0 
NAPROXEN BOUND (mMol/L) 
SERUM ALBUMIN (mMol/L) V = 
FIGURE 3. 
Scatchard plots of naproxen-albumin binding. Open c i rc les (o) 
represent the data on 8 healthy young volunteers; dots ( ·) represent 
the data on б elderly patients. 
Figure 3 gives the Scatchard plots derived from the data of a l l serum 
samples determined in both groups. On the basis of these plots 
naproxen binding a f f i n i t y to albumin, as characterized by the 
association constant ( K a ) , was s igni f icant ly lower in elderly 
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p a t i e n t s (p<0.001): 
Ka ( e l d e r l y ) : 2.0 ± 0.5 1/μΐηο1. 
Ka (young) : 5.5 ± 0.4 1/μπιο1. 
The number of binding s i t e s per albumin molecule ( η ) , assuming one 
s ingle class was: 
η ( e l d e r l y ) : 1.1 ± 0.2 
η (young) : 0.9 + 0.2. 
DISCUSSION 
Naproxen pharmacokinetics in the aged were studied by Upton et a l . 
(1984) in a s i n g l e and m u l t i p l e dose study wi th 375 mg oral naproxen 
twice d a i l y in young and e l d e r l y heal thy male v o l u n t e e r s . Mean 
steady-state plasma concentrat ions were i n d i s t i n g u i s h a b l e , but the 
unbound naproxen f r a c t i o n was doubled in the e l d e r l y males, together 
with a 50% decrement of the i n t r i n s i c c learance. In a r e c e n t l y 
published study, McVerry et a l . (1986) found in g e r i a t r i c i n - p a t i e n t s 
a f t e r a 21-day course of therapy with 500 mg naproxen twice d a i l y a 
higher mean pre-dose concentrat ion as wel l as a higher mean pre-dose 
unbound concentrat ion of the d r u g , as compared wi th middle-aged 
p a t i e n t s . Our study of m u l t i p l e large doses of naproxen provides 
f u r t h e r data on a l t e r e d naproxen pharmacokinetics in aged p a t i e n t s . 
The b i o a v a i l a b i l i t y of oral naproxen in young volunteers 
approximates 100% (Runkel et a l . 1972). For c a l c u l a t i n g pharmaco­
k i n e t i c p a r m e t e r s we have assumed an unaltered b i o a v a i l a b i l i t y o f 
naproxen in the e l d e r l y in view of the completeness of i n t e s t i n a l 
drug absorption in the aged (Greenblatt et a l . , 1982). However, we 
preferred to use the symbol CL/F e t c . , because one should perform 
both ora l and intravenous studies in the e l d e r l y t o be c e r t a i n about 
naproxen b i o a v a i l a b i l i t y . In the p a t i e n t s tak ing other medication as 
w e l l , naproxen-druq i n t e r a c t i o n at the s i t e of absorption was avoided 
by postponing the intake of co-medication on the day of study. 
Moreover, the nature of the co-medication makes i n t e r f e r e n c e w i t h 
naproxen p r o t e i n binding u n l i k e l y . 
Over 99% of the serum naproxen i s bound t o albumin; the s i g n i f i c a n t 
decrease of serum albumin in the e l d e r l y p a t i e n t s expla ins the 
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lowered Среа^, smaller AUC(0-12) and larger V/F-BW"1. Serum 
albumin concentration f a l l s with increasing age (Greenblatt, 1979). 
Also an inflammatory disease, e.g. an episode of active disease in 
the course of rheumatoid a r t h r i t i s , is associated with decreased 
serum albinin (Baum & Z i f f , 1985, Van Den Ouweland, 1986). The two 
patients with rheumatoid a r t h r i t i s in our study did not show more 
pronounced hypoalbuminaemia: 34 and 36 g/1 respectively. The mean 
serum albumin concentration in the elderly was 35 g/1; in our opinion 
their hypoalbuminaemia was attr ibutable to age. The Scatchard plots 
indicate that naproxen binding a f f i n i t y to albumin is s ign i f icant ly 
smaller in elderly patients. In addition to age-related hypoalbumin­
aemia i t results in an increment in serum unbound naproxen, which is 
maintained over the dose interval by a decrease of (CL/F)U to 40% 
of the value in young volunteers. 
In man, conjugation and demethylation of naproxen are the main 
metabolizing steps before urinary excretion; v i r t u a l l y no unchanged 
drug is excreted (Upton et a l . , 1980). We must assume that the 
moderate impairment in kidney function of elderly subjects cannot 
explain the reduction in (CL/F)U. The l i ver représents the major 
s i te of drug metabolism. The extremely high values of (CL/F)U in 
both elderly and young subjects (281 and 713 1/h respectively) in 
comparison with estimated hepatic pi asna f low, approximately 50 1/h 
in young adults, suggest that not only the unbound drug but also part 
of the albumin-bound naproxen is extracted. 
In the aged, l iver size in absolute terms as well as relat ive to body 
weight is diminished and hepatic blood flow is reduced by 40-45%; 
moreover, complex alterations in biotransformatory pathways have been 
observed (Greenblatt et a l . , 1982). Nevertheless phase I I reactions 
in the hepatocyte (drug conjugations) appear to be unaffected by age 
and the extraction of low clearance drugs is re la t i ve ly blood flow-
independent. The influence of age on hepatic uptake processes in man 
is unknown. In patients with alcoholic cirrhosis a quant i tat ively 
similar loss of unbound naproxen clearance has been shown (Williams 
et a l . , 1984); however, the mu l t i p l i c i t y of anatomical and metabolic 
changes due to cirrhosis obviously is not identical with the age-
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related alterations in l iver histology and function. One can only 
speculate as to which of the described mechanisms in naproxen 
elimination is hampered to a certain extent with increasing age and 
thus causes the loss of (CL/F)U in elderly patients. 
In contrast with the findings of McVerry et a l . (1986) we observed a 
lower mean pre-dose total serum naproxen concentration in the aged 
patients: 48 ± 11 mg/1 in our study as compared with 60 t 19 mg/1. 
The lower serum albumin concentration (34+5 g/1) in our patients 
versus 40.3+3.5 g/1 in the study of McVerry readi ly explains th is 
difference. 
I t must be noted that for judgeing of naproxen pharmacokinetics in 
the elderly tota l drug figures are only part ly informative. The lower 
serum concentrations and even increased CL/F of the tota l drug are 
associated with a decreased (CL/F)U and consequently higher unbound 
drug concentrations. Naproxen h a l f - l i f e is not s ign i f icant ly changed 
because of paral lel changes in apparent volume of d is t r ibut ion with 
clearance for both total and unbound naproxen. The differences 
between t l / 2 and ( t l / 2 ) u i n e a c h individual (p<0.01) must be the 
result of the concentration-dependent unbound f r a c t i o n , as shown in 
Figure 2. V/F»BW"1 is largely determined by the intravascular 
albumin content. The high values of (V/F)U«BW~1 r e f l e c t extra-
vascular d i s t r i b u t i o n ; the smaller (V/F)U«BW"1 in the elderly 
possibly results from loss of naproxen tissue binding. 
An increase in unbound drug fractions in the aged has been reported 
for a number of albumin-bound acidic drugs, including NSAID (Wallace 
& Verbeeck, 1987). This can only part ly be explained by a lowered 
5егші albumin concentration. The decrement in naproxen-albumin 
binding a f f i n i t y in the aged, as described in th is study, is obscure. 
In most c l i n i c a l situations the importance of such findings is 
modest, but i f the protein-unbound drug concentration is responsible 
for desired pharmacological or undesired adverse effects i t must be 
anticipated that the aged patient has an enhanced response to the 
"normal" dose. 
Considering our results and the volunteer data of Upton et a l . (1984) 
i t remains advisable to start naproxen treatment in the aged patient 
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at a low dosage, e.g. 250 mg oral ly twice dai ly . When no suff ic ient 
therapeutic effect is obtained and this dose has not caused side 
ef fects, an increase in dosage is j u s t i f i e d . 
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NAPROXEN KINETICS AND DISEASE ACTIVITY IN 
RHEUMATOID ARTHRITIS: A WITHIN-PATIENT STUDY 
FA van den Ouwel and, FWJ Gribnau, CAM van Ginneken, 
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LIST OF ABBREVIATIONS 
AUCo_i2 area under the concentration-time curve 
during one dose interval 
CQ serum c o n c e n t r a t i o n at t ime 0 
Cpeak h i g h e s t measured serum c o n c e n t r a t i o n 
CI clearance 
F b i o a v a i l a b i l i t y 
ESR erythrocyte sedimentation rate 
к rate constant 
Ka binding a f f i n i t y association constant 
η number of independent binding sites 
t l /2ß terminal h a l f - l i f e 
u variables concerning unbound drug measurements 
ν r a t i o of drug bound/albumin 
V apparent volume of d ist r ibut ion 
SUMMARY 
The effects of rheunatoid a r t h r i t i s disease a c t i v i t y on pharmaco­
kinetics of the highly albumin-bound non-steroidal anti-inflammatory 
drug naproxen were studied. Total and protein-unbound serum 
concentrations were determined in six (male and female) patients with 
classic rheumatoid a r t h r i t i s and active polyart icular inflammation 
during chronic therapy with 500 mg oral naproxen twice da i ly ; the 
study was repeated at a time when major improvement in disease 
a c t i v i t y had been achieved. 
Naproxen was measured by high-performance l iquid chromatography and 
unbound naproxen concentrations were assayed in buffer after 
equi l ibr imi dialysis of serum samples. 
Active disease in patients with rheumatoid a r t h r i t i s is commonly 
associated with hypoalbuminemia: in our patients serum albumin 
concentration was 30+4 g/1 versus 41±2 g/1 (mean ± S.D.) at the time-
of major improvement. Total naproxen concentrations were s igni f icant­
l y lower in the period of active disease, together with a larger 
apparent volume of d i s t r i b u t i o n (10.6+1.8 1 versus 8.4+1.3 1; p<0.05) 
and tota l body clearance (0.79+1.8 1/h versus 0.59+0.14 1/h; 
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p<0.001). 
Peak unbound naproxen concentrations were 29±19* (p<0.05) lower at 
the time of improvement (0.40+0.22 mg/1 versus 0.26+0.11 mg/1), but 
unbound trough concentrations (0.06+0.03 mg/1 versus 0.06+0.03 mg/1) 
and unbound concentrations measured after one dose interval up to 
60 hours post-dose were similar. The unbound clearance was found 
diminished during the period of active disease (390+277 1/h) in 
comparison with improvement (488±343 1/h; p<0.05). 
Clinical implications of the pharmacokinetic alterations induced by 
active polyarticular inflammation in patients with rheumatoid 
arthritis on chronic naproxen therapy are discussed. 
INTRODUCTION 
In the managenent of inflammatory synptoms in rheumatoid arthritis, 
non-steroidal anti-inflammatory drugs (NSAID) have gained a firm 
placel. Data on pharmacokinetics of the available NSAID generally 
stem from volunteers; few studies have tried to assess the possible 
effects of rheumatoid arthritis on drug disposition in patients^. 
Recently we have shown alterations in naproxen kinetics in patients 
with rheumatoid arthritis during active polyarticular inflammation 
as compared with healthy young male volunteers^. Due to the 
extensive albumin binding of naproxen, patients had lower serum drug 
concentrations during the dose interval on chronic intake of 500 mg 
oral naproxen twice daily, corresponding with their lower serum 
albumin. In contrast with total drug kinetics, unbound serum 
concentrations of naproxen were found significantly increased in 
patients with active rheumatoid arthritis, together with a reduction 
in clearance and apparent volume of distribution of unbound drug. 
Hypoalbiminemia is a common feature associated with exacerbations in 
disease activity of rheumatoid arthritis, due to an increased 
catabolismi or a combination of catabolism and interleukin-1-
dependent reduced albumin synthesis^. Apart from the lower serum 
albumin concentration, other causes of change in naproxen kinetics in 
patients with rheumatoid arthritis may be: a diminished hepatic drug 
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TABLE I . DEMOGRAPHIC AND CO-MEDICATION DATA OF б PATIENTS WITH RHEUMATOID ARTHRITIS, STUDIED IN A 
PERIOD OF ACTIVE POLYARTICULAR INFLAMMATION ( I ) AND IN MAJOR IMPROVEMENT OF DISEASE 
ACTIVITY ( I I ) 
Gender/age* 
years 
A M/49 
В F/56 
С F/59 
D F/62 
E M/63 
F F/64 
Height 
cm 
179 
170 
166 
168 
175 
173 
Body 
I 
88 
77 
72 
58 
69 
57 
Weight 
kg 
I I 
84 
76 
73 
65 
75 
56 
Smoker 
I I I 
+ + 
- + 
-
-
- -
— — 
Co-medication** 
I I I 
1(150) 1(1500) 
1(50,2,3,4 1(880),5(2) 
1(150),6 1(1500) 
2,5(10),7 5(5),8 
1(2800),9 1(4200) 
1(150),10 1(200),11(400) 
Ti 
I 
me 
and 
interval between 
I I in months 
11.5 
8 
8.5 
12 
15.5 
7.5 
* age is given as the mean age of I and I I 
** comedication numericals: mg) 1. aurothioglucose ( t o t a l cunulative intramuscular dose in 
2. acetaminophen 2-3 g/day 
3. d-propoxypheneHCL 150 mg at night 
4. temazepam 10 mg at night 
5. prednisone ( d a i l y dose in mg) 
6. oxazepam 10 mg at night 
7. azathioprine 100 mg/day 
8. sulphasalazine 2 g/day, stopped 60 h. before the study unti l the end 
9. Cimetidine 600 mg/day, last dose 8 h. before the study, then stopped 
10. acenocoumarol stopped 60 h. before the start of the study 
1 1 . gold sodium thiomalate ( t o t a l cunulative intramuscular dose In mg) 
metabolism and a modified naproxen albumin binding affinity^. We 
therefore studied naproxen pharmacokinetics in patients with 
rheunatoid arthritis on two different occasions: first at a time of 
disease exacerbation and then at a time when remission or at least 
major improvement in disease activity had been achieved. 
PATIENTS & METHODS 
Naproxen pharmacokinetics were studied in six patients with 
rheumatoid arthritis during active polyarticular inflammation 
(period I), as well as at a time when major improvement of disease 
activity had been achieved (period II). At the time of period I the 
patients were hospitalized in the Rheumatology ward, for institution 
of medical therapy and supportive measures; the study during period 
II was performed at the patients' residences. Demographic data are 
listed in Table I. All patients were suffering from seropositive 
classic rheumatoid arthritis according to the criteria of the 
American Rheumatism Association^. Period II studies were performed 
at a time when the proposed criteria for a complete remission of 
rheumatoid arthritis were nearly or completely fulfil led**. 
A complete ranission was achieved in patient Α, Β, E and F; this 
means that five or more of the following requirements were fulfilled 
for at least two consecutive months: duration of morning stiffness 
not exceeding 15 minutes, no fatigue, no joint pain by history, no 
joint tenderness or pain on motion, no soft tissue swelling in joints 
or tendon sheaths, ESR < 30 mm/h for a female or < 20 mm/h for a 
male. Patients С and D had an ESR of 32 and 43 mm/h respectively, and 
both had three swollen joints; the other criteria were met. 
Physical examination before the study revealed no extra-articular 
manifestations of rheumatoid arthritis and no clinically important 
other diseases were found. After appropriate investigation the 
anemia in these patients was diagnosed as anemia of chronic 
disorders^. Hemoglobin concentrations and other laboratory assess­
ments are listed in Table II. The findings of an elevated ESR, 
elevated C-reactive protein and hypoalbjninemia are consistent with 
generalized inflammation. TTiere was no significant proteinuria and no 
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TABLE I I . LABORATORY FINDINGS IN THE PATIENTS WITH RHEUMATOID ARTHRITIS DURING ACTIVE DISEASE ( I ) AND MAJOR 
IMPROVEMENT IN DISEASE ACTIVITY ( I I ) 
hemoglobin ESR 
reference 
values: M 8.5-11 M <10 
F 7.5-10 F <21 
rtmol/l mm/h 
A 
В 
С 
D 
E 
F 
I 
8.1 
6.6 
5.3 
5.3 
6.1 
6.2 
II 
8.5 
8.3 
7.7 
7.6 
8.1 
6.6 
I 
55 
70 
113 
80 
88 
77 
II 
16 
15 
32 
27 
5 
43 
C-reactive creatinine 
protein 
<6 M 60-110 
F 50-90 
mg/l μπιοΐ/ΐ 
I II I II 
23 10 67 67 
47 4 75 66 
150 6 67 75 
132 20 64 56 
143 18 99 79 
21 26 60 53 
aspartate amino alkaline 
transferase phosphatase 
<25 <120 
U/l U/l 
I II I II 
17 19 90 105 
22 17 102 75 
14 13 120 143 
23 16 86 31 
15 13 87 76 
20 21 76 93 
γ-qlutamyl albumin 
transpeptidase 
M <40 37-47 
F <30 
U/l g/1 
I II I II 
12 13 34 39 
20 12 35 44 
26 13 25 41 
50 20 31 41 
18 17 27 40 
20 8 29 39 
sign of hepatic disease. 
Medication 
Naproxen was started two to five weeks before the pharmacokinetic 
study; the patients received 500 mg orally twice daily in tablets 
of 250 mg NaprosyneR (Sarva Syntex Nederland, Rijswijk, The 
Netherlands). All except patient D continued naproxen therapy after 
period I, but at a lower dosage as disease activity diminished. In 
patient D, naproxen was changed to Ibuprofen four months before the 
study of period II. At least one week before period II all patients 
were reinstituted on twice daily 500 mg naproxen. On the first day of 
the study 500 mg naproxen was given orally with breakfast at time 0; 
the drug was then omitted for the next 60 hours. 
Co-medication is listed in Table I; on the first day of the study the 
morning dose of any medication other than naproxen was postponed 
until noon. As indicated in Table I, in patient E Cimetidine was 
discontinued 8 hours before study I, in patient F acenocoumarol was 
discontinued 60 hours before study I and in patient D sulphasalazin 
was stopped 60 hours before study II until the end of study. During 
the period of study I, analgesics were administered if needed: 
patient В and 0 used acetaminophen and d-propoxypheneHCl. During 
study II the patients felt no need for analgesics. 
Blood sampling and urine collection 
Blood samples for total and unbound serun naproxen determinations 
were taken at time 0, immediately before ingestion of the drug, and 
after 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 36, 48 and 60 hours. After 
separation of blood cells, serum was stored at -2CPC until analysis. 
At time 0 an indwelling catheter was placed in an antecubital vein. 
Venous access was kept patent by injection of 50 U heparin sodium 
solution in 0.5 ml 0.9% NaCl into the rubber capped catheter after 
each blood sampling. The catheter was removed after 12 hours and 
further samples were obtained by repeated venipuncture. 
At time 0, blood was taken for assessment of ESR, hemoglobin 
concentration, and serum concentration of C-reactive protein, 
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alkaline phosphatase, aspartate amino transferase, γ-glutamyl trans­
peptidase, creatinine and albumin. Laboratory tests were performed 
according to standard procedures. The freely voided urine was 
collected at intervals of 12 hours and a sample was stored at -2CPC 
for determination of naproxen and desmethylnaproxen conjugates. 
Naproxen determinations 
Naproxen in serum and urine samples was assayed by high-performance 
l i q u i d chromatography and spectrofluorophotometric detection; the 
coeff ic ient of variat ion for total serum naproxen (concentration 
range: 1-125 mg/1) with this method is 1.?.%1Q. The unbound serum 
naproxen concentration in the samples was determined in buffer after 
equilibrium dialysis at З^С for 5.5 hours against isotonic Sörensen 
phosphate buffered saline with pH 7.4. The dialysis cel l contained 
1 ml serum and 1 ml buffer, separated by a cellulose dialysis 
membrane (Cuprophane^ M150). Adsorption of the drug to the membrane 
was negl ig ible. The coeff ic ient of variat ion over the concentration 
range 0.001-1 mg/1 was 4.2%. Storage of samples at -2(PC for up to 
one year did not alter the unbound drug concentrations. 
Pharmacokinetic parameters 
B ioavai lab i l i ty of 100% was assumed for calculation of pharmaco-
kinetic parameters. Kinetic data on intravenous administration of 
comparable doses of naproxen to test th is assumption are not 
available, we therefore preferred to use the symbols Cl/F (clearance/ 
b ioavai lab i l i ty ) and V/F (volume of d is t r ibut ion/b ioavai lab i l i ty ) 
throughout the text . Naproxen Cl/F ( in 1/h), under the assumption of 
steady state kinetics at time 0, was calculated as: 500/AUCo-l2» 
where 500 is the dose in mg and AUCo-12 is the area under the 
concentration-time curve during one dose interval of 12 hours in 
mgh/1. The AUCo-12 was estimated using the linear trapezoidal ru le. 
An apparent volume of d is t r ibu t ion /b ioava i lab i l i t y (V/F, in 1) was 
calculated as: SOO/iAUCQ-^'k), where к is the rate constant ( in 
h~l) obtained from the slope of the log-linear regression l ine 
through the last three time points of the dose interva l : 4, 8 and 12 
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hours. The terminal ha l f - l i f e (t l /2ß in h) of naproxen was calculated 
from the slope of the log-linear regression l ine through the time 
points 8, 12, 24, 36, 48 and 60 hours post-dose. From the values of 
unbound serum naproxen concentrations identical calculations were 
performed to obtain the pharmacokinetic parameters for unbound 
naproxen. 
Albumin binding 
Naproxen-albumin binding a f f i n i t y was studied in a plot according to 
Scatchardll# with the assumption of a single class of binding sites 
per albumin molecule, the binding a f f i n i t y constant (Ka) was 
derived from the slope of the least squares regression l ine of 
v/unbound naproxen concentration plotted against v, where ν is the 
rat io of bound naproxen concentration/albumin concentration. To 
convert the concentration of albunin from g/1 to mmol/1, a molecular 
weight of 69,000 was used. The intercept of the ν axis is the number 
(n) of independent binding sites per albumin molecule. 
Stat is t ica l analysis 
Data obtained in active disease (period I ) and in major improvement 
of rheumatoid a r t h r i t i s (period I I ) were analysed for s ignif icant 
differences by the two-tailed t-test for paired samples. Spearman's 
rank correlat ion coeff icient was used to analyse for a s ignif icant 
relationship between parameters. 
Study ethics 
The study was approved by the Ethics Committee of the University 
Hospital St Radboud. Patients gave verbal informed consent. 
RESULTS 
Together with disease act iv i ty-related alterations in hemoglobin, ESR 
and C-reactive protein, a signif icant increase in serin albumin 
concentration was found at the time of improvement in rheumatoid 
a r t h r i t i s : 30±4 g/1 in period I versus 41±2 g/1 in period I I ; 
ρ < 0.001. Liver and kidney function tests showed an occasional r ise 
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FIGURE 1. 
Total serum naproxen concentrations in six patients with rheumatoid 
a r t h r i t i s after chronic treatment with 500 mg oral naproxen twice 
dai ly . The last dose was administered at time 0. Data are presented 
at the time of active polyarticular inflammation ( · ) , and at a time 
when major improvement in disease act iv i ty had been achieved (o) 
Bars indicate standard error of the mean. 
or f a l l without c l i n i c a l importance. Individual measurenents are 
shown in Table I I . 
Naproxen serum concentrations over time are graphically depicted in 
Figure 1 for tota l and Figure 2 for unbound drug. The points from 
time 0, the trough drug level at steady state, u n t i l 12 hours post-
dose represent the naproxen concentrations over one dose interval . 
Total naproxen concentrations were higher in patients with rheumatoid 
a r t h r i t i s at the time of improvement in disease a c t i v i t y : both trough 
and peak concentrations during the dose interval showed signif icant 
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FIGURE 2. 
Unbound serum naproxen concentrations in six patients with rheunatoid 
a r t h r i t i s in active disease ( · ) , and improvement (o) . Bars indicate 
standard error of the mean. 
differences. Pharmacokinetic parameters are l is ted in Table I I I . Cl/F 
and V/F were s ign i f icant ly larger in active disease. 
Unbound pharmacokinetics are l isted in Table IV. In contrast with 
tota l drug kinetics (Cl/F)u in al l patients was found to be larger 
at the time of improvement in rheumatoid a r t h r i t i s (390±277 1/h in 
period I versus 488+343 1/h in period I I ; ρ < 0.05). Unbound naproxen 
trough concentrations, as well as the measurements at time points 
after the dose i n t e r v a l , were indistinguishable in active disease and 
in improvement. Unbound peak concentrations in a l l patients were 
higher in active disease; however, individual differences in mg/1 
showed a large v a r i a b i l i t y . Mean of period I : 0.40+0.22 mg/1 versus 
0.26t0.11 mg/1 in period I I ; 0.05 < ρ < 0.1). Normalization to 
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TABLE I I I . TOTAL SERUM NAPROXEN 
RHEUMATOID ARTHRITIS, 
INFLAMMATION ( I ) AND 
ACTIVITY ( I I ) 
Cu cpeak 
mg/1 mg/1 
A 
6 
С 
D 
E 
F 
Ρ 
I 
27.5 
25.9 
39.5 
44.7 
43.0 
43.3 
< 0 
II 
28.0 
52.2 
79.5 
56.2 
66.0 
64.4 
.02 
I 
70.3 
103.1 
90.9 
85.8 
73.0 
82.0 
II 
80.0 
104.9 
125.6 
113.4 
99.2 
107.2 
< O.Ol 
mean 37.3 57.7 84.2 105.1 
S.D. 8.4 17.3 12.1 15.2 
TABLE IV. UNBOUND SERUM NAPROXEN 
(Cu)u ( c peak)u 
mg/1 mg/1 
A 
В 
С 
D 
E 
F 
Ρ 
mean 
S.D. 
I 
0.03 
0.03 
0.09 
0.05 
0.07 
0.08 
Ν. 
0.06 
0.03 
II 
O.Ol 
0.04 
0.09 
0.05 
0.06 
0.10 
S. 
0.06 
0.03 
I 
0.11 
0.42 
0.73 
0.55 
0.28 
0.32 
II 
0.10 
0.22 
0.32 
0.42 
0.20 
0.29 
0.05<p<0.1 
0.40 
0.22 
0.26 
0.11 
PHARMACOKINETICS IN PATIENTS WITH 
STUDIED IN ACTIVE POLYARTICULAR 
IN MAJOR IMPROVEMENT OF DISEASE 
Cl/F V/F t i ß 
1/h 1 h 
I 
0.99 
0.79 
0.72 
0.69 
0.82 
0.73 
II 
0.86 
0.54 
0.44 
0.55 
0.59 
0.54 
< 0.001 
0.79 
0.11 
0.59 
0.14 
I 
11.4 
9.7 
12.7 
8.6 
9.0 
12.4 
II 
8.5 
5.8 
9.0 
9.3 
8.4 
9.4 
< 0.05 
10.6 
1.8 
8.4 
1.3 
I 
12.2 
14.2 
19.0 
16.8 
13.9 
21.6 
N. 
16.3 
3.5 
II 
12.8 
15.5 
27.4 
20.3 
14.4 
21.0 
S. 
18.6 
5.4 
PHARMACOKINETICS 
( C l / F ) u (V /F ) u ( t j p ) u 
1/h 1 h 
I 
937 
360 
170 
229 
299 
344 
<0, 
390 
277 
II 
1174 
377 
258 
296 
453 
369 
.05 
488 
343 
I 
9830 
1680 
868 
892 
1221 
2093 
N. 
2764 
3494 
II 
7680 
1430 
1291 
1633 
2689 
2179 
S. 
2817 
2438 
I 
10.1 
16.6 
15.8 
12.9 
9.8 
13.5 
N. 
13.1 
2.8 
II 
12.8 
15.1 
15.7 
12.7 
10.9 
14.9 
S. 
13.7 
1.9 
percentage change resulted in a significant mean reduction of Cpeak 
from active disease (I) to improvement (II) with 29+19%; ρ < 0.02. 
(V/F)u and (tl/2p)u showed no significant alterations due to marked 
individual changes in both directions without an obvious trend. 
The individual albumin-naproxen binding affinity constants (K
a
) 
showed a tendency toward increased binding at the time of 
improvement: see Table V. With the exception of patient F, all K
a 
values were higher in remission, with a statistically significant 
increase at a ρ value < 0.05 in patients С and D. The number of 
binding sites (n), assuming one class, did not change: n=0.96±0.09 in 
active disease and n=0.91±0.07 at the time of improvement in 
rheunatoid arthritis. 
TABLE V. NAPROXEN-ALBUM IN BINDING AFFINITY CONSTANTS 
(K
a
 in Ι.μτηοΓ1), DERIVED FROM SCATCHARD PLOTS 
IN ACTIVE DISEASE (I) AND IMPROVEMENT (II) 
I II 
A 3.4 ± 0.5 4.2 ± 0.7 
В 2.6 ± 0.5 4.6 t 0.6 
С 2.6 ± 0.3 * 5.4 t 0.4 
D 3.8 t 0.4 * 5.5 ± 0.4 
E 4.4 + 0.8 5.3 ± 0.4 
F 6.1 ± 0.5 5.1 t 0.7 
* p<0.05 
Individual data on the urinary excretion of both naproxen and 
desmethyl naproxen conjugates during the dose interval (0-12 hours 
post-dose), as well as the cumulative excretion measured over 
60 hours are listed in Table VI. The excretion of naproxen and 
desmethylnaproxen conjugates was similar in period I and II during 
one dose interval. The urinary recovery of the total intake of 
naproxen (500 mg) was 55+6%. The cumulative excretion of naproxen and 
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TABLE VI. URINARY EXCRETION OF THE TOTAL OF 
CONJUGATES (in mg naproxen equival 
PERCENTAGE OF TOTAL EXCRETION IN A 
excretion during the dose interval 
t o t a l conjugates DMNC* 
mg % 
A 
В 
С 
D 
E 
F 
Ρ 
mean 
S.D. 
I 
319 
241 
296 
268 
271 
259 
Ν. 
276 
27 
II 
341 
251 
289 
257 
279 
240 
S. 
276 
36 
I II 
15 12 
19 13 
20 26 
15 14 
21 17 
21 19 
N.S. 
18 17 
3 5 
ROXEN CONJUGATES AND DESMETHYLNAPROXEN 
s) AND DESMETHYLNAPROXEN CONJUGATES AS 
VE DISEASE ( I ) AND IMPROVEMENT ( I I ) 
cumulative excretion unti l 60 hours 
t o t a l conjugates DMNC* 
mg % 
I II 
498 508 
372 420 
445 556 
504 506 
432 506 
474 483 
).05<p<0. 1 
454 497 
I 
15 
18 
20 
15 
22 
23 
N. 
19 
II 
14 
15 
25 
15 
18 
22 
S. 
18 
* DMNC denotes desmethylnaproxen conjugates 
desmethylnaproxen conjugates was higher in al l patients at the time 
of improvement; however, inter- indiv idual ly differences were large. 
Mean cumulative excretion to 60 hours post-dose in period I was 
454+49 mg and in period I I i t was 497±44 mg; 0.05 < ρ < 0.1. Extra­
polation to i n f i n i t y reveals a comparable r e s u l t : a 12+11% higher 
cumulative excretion of naproxen equivalents at the time of 
improvement; ρ < 0.05. The percentage of naproxen equivalents 
excreted as desmethylnaproxen was similar in period I and I I . 
DISCUSSION 
The importance of c l i n i c a l pharmacokinetic studies l i k e ours is that 
they provide the figures of kinetic parameters val id in dai ly 
c l in ica l practice. I t is therefore inevitable that study entry 
c r i t e r i a are not r i g i d . 
Pharmacokinetic studies with naproxen in healthy volunteers showed 
complete absorption after oral administration of the drug with or 
without food, in doses up to 4 gl2-14# Non-linear k inet ics, i . e . 
decreasing increments in AUC upon the intake of subsequent higher 
dosages have been found, probably due to saturation of naproxen 
bindingl3,15# After conjugation, the elimination of naproxen and 
i t s main metabolite desmethylnaproxen follows the renal route; 
v i r t u a l l y no unchanged drug is excreted^. 
In our patients with rheumatoid a r t h r i t i s tota l and unbound naproxen 
kinetics evidently show alterations related to a c t i v i t y of the 
disease: in the period of polyarticular inflammation, lower total 
serum concentrations are accompanied by a variable but intra-
indiv idual ly always higher peak concentration of unbound drug. The 
f i r s t and most simple explanation for these findings is that hypo-
аІЬшпіпетіа in patients with active rheumatoid a r t h r i t i s leads to 
saturation of protein binding at a lower total naproxen 
concentration. Indeed, the percentual increase in serum albumin 
concentrations as disease act iv i ty diminished, was s i g n i f i c a n t l y 
correlated with the percentage increase in the corresponding peak 
total serum concentrations of naproxen (r=0.89; ρ < 0.05). I f only 
saturation of albumin binding would be of importance, one would 
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expect higher unbound naproxen fractions over the dose interval and 
no or only short-term elevations in unbound drug concentrations^. 
However, in a l l patients unbound naproxen concentrations were found 
elevated at the time of polyarticular inflammation; consequently 
(Cl/F)u was diminished in period I as compared with improvement. 
The similar excretion of naproxen metabolites during the dose 
interval of both study periods makes f luctuations in b ioava i lab i l i ty 
unl ikely. The urinary recovery of 55+6% of the oral dose corresponds 
with findings in volunteers^lG. 
Factors interfer ing with naproxen kinetics were avoided where 
possible, but could not be eliminated with certainty. Drug 
interactions at the si te of absorption were prevented by postponing 
co-medication.The study was timed so that drugs possibly interfering 
with naproxen disposit ion could be discontinued. Nevertheless, co-
medication was more extensive in the period of active polyarticular 
inflammation, than at the time of improvement. Displacing drugs lower 
the value of К
а
18,19 ; moreover in patients with active rheumatoid 
a r t h r i t i s , the presence of a modified albumin s t r u c t u r e ^ and 
endogenous inh ib i tors are other possible origins of lowered Ka 
values. In v i t r o protein binding of four d i f ferent NSAID in serun of 
ten patients with rheumatoid a r t h r i t i s was not found different from 
that in control patients with o s t e o a r t h r i t i s ^ ! . In our study 
however, s igni f icant decrements in naproxen-albumin binding a f f i n i t y 
in at least two patients were calculated at the period of active 
disease. A decrease in Ka allows for higher unbound drug fract ions, 
and only together with a reduction in (Cl/F)u does th is result in 
higher unbound drug concentrations. Alterations in Ka may be of 
interest with regard to finding a perfect inverse relationship ( r=- l ) 
between the differences in Ka in period I and I I and corresponding 
elevations of unbound naproxen peak concentrations. 
The consequences of disease act iv i ty of rheumatoid a r t h r i t i s for 
(Cl/F)u of naproxen in the patients of th is study are obvious. 
There are no arguments to hypothesize interference of rheunatoid 
46 
ar th r i t i s disease act iv i ty with the renal excretion of conjugated 
compounds. As shown by the urinary excretion data, the percentage of 
desmethylnaproxen in total metabolite excretion is similar in 
periods I and I I . Also the total excretion of naproxen metabolites is 
similar in the dose interval of periods I and I I . These findings make 
alterations in the pathways of metabolism of naproxen less l i k e l y , 
but not impossible. The cumulative excretion of naproxen metabolites 
to 60 hours post-dose tended to be larger at improvement, but did not 
reach s ta t is t i ca l significance. Also, no signi f icant relationship was 
found between the increase in urinary naproxen equivalent excretion 
and the decrease in V/F. As expected, V/F decreased at the time of 
Improvement in disease act iv i ty as serim albumin concentrations 
returned to normal levels. 
I t appears that the presence of a state of generalized inflammation 
in the patients with active disease hampers hepatic metabolism of 
naproxen, and the results of this study suggest that there is a 
decrease in the rate of hepatic uptake of unbound drug from plasma or 
in intra-hepatocytic processes. 
Hepatic clearance of protein-bound drug is usually described as 
depending on i t s extraction ra t io ( th is is the f ract ion of drug 
removal in a single pass through the l i v e r ) . Drug clearance is blood 
flow-dependent in the case of a high extraction r a t i o , or dependent 
on the unbound drug concentration in the case of a low extraction 
ratio22. Naproxen total drug clearance (0.6-0.8 1/h) in relat ion 
to an estimate of hepatic plasma flow, 50 1/h in young adults, 
indicates a low extraction ra t io . From the figures of (Cl /F)u : 
390 1/h in active disease and 488 1/h in improvement, i t follows that 
the extraction of naproxen in both situations exceeds the unbound 
drug f rac t ion . Naproxen bound to albumin therefore forms a 
substantial part of the hepatic uptake. A lower serin albimin serum 
concentration, as in active polyarticular inflanmation of rheumatoid 
a r t h r i t i s , might lower the clearance of naproxen; however, the 
opposite is found: tota l drug clearance is higher in the presence of 
hypoalbuminemia. 
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We conclude that rheumatoid arthritis patients with active poly-
articular inflammation have altered naproxen phannacokinetics, if 
compared with a period of improvement in disease activity. Together 
with the lower albumin concentration in active disease a larger V/F 
and Cl/F is found, without significant change in tl/2ß. Unbound 
naproxen kinetics show a variable, but significant decrement in 
(Cl/F)u, consequently higher unbound peak concentrations after 
ingestion of the drug, but indistinguishable unbound trough 
concentrations. 
Factors possibly explaining the lowered (Cl/F)u in active disease 
are diminished hepatic uptake of unbound naproxen from plasma or a 
hampered metabolism of the drug. 
The clinical implications of the findings are: 
- a possible beneficial effect of hypoalbumi ηetnia in patients with 
rheimatoid arthritis and active polyarticular inflammation on the 
anti-inflammatory effect of naproxen, assuming that unbound drug 
levels correlate with therapeutic effect; 
- the possibility of an increased incidence of adverse drug reactions 
to naproxen in patients with severe hypoalbuminemia; 
- the limited value of total drug concentration ¡neasurenents as a 
decision aid for dose adjustments. 
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Hypoalbuminaemia and Naproxen Pharmacokinetics 
in a Patient with Rheumatoid Arthritis 
FA Van Den Ouweland, FW J Gnbnau, Y Tan, 
CA M Van Ginneken and LB A Van De Putte 
Institute of Pharmacology, Division of Clinical Pharmacology and Pharmacokinetics, 
Department of Medicine, Division of Clinical Pharmacology, and Department of 
Medicine, Division of Rheumatology University Hospital Sint Radboud, Nijmegen 
The effects of rheumatoid arthritis (RA) disease 
activity on non-steroidal anti-inflammatory drug 
(NSAID) pharmacokinetics have not been exten­
sively studied (Verbeeck et al 1983) Changes in 
serum albumin concentration together with fluc­
tuations in disease activity could give rise to al­
terations in the pharmacokinetics of highly albu­
min-bound drugs In RA patients, serum albumin 
concentrations are frequently lowered (Baum &. Ziff 
I98S) as a result of increased catabolism (Wikin-
son et al 1965) Dunng exacerbations of RA an 
increase in catabolism can explain decrements in 
serum albumin concentration, paralleling indices 
of disease activity (Ballantyne et al 1971 ) This case 
report desenbes the changes in naproxen phar­
macokinetics dunng long term administration of 
naproxen to a patient with RA, as disease activity 
had diminished and the depressed serum albumin 
concentration returned to normal 
Case Report 
Classic RA was diagnosed in a female aged 58 
years She had had joint complaints for 1 year and 
had morning stiffness of 1 hour duration Physical 
examination revealed sy m metrical polyarticular 
inflammation subcutaneous nodules or other ex­
tra-articular manifestations of RA were absent The 
number of swollen joints was 25, that of tender 
joints was 4 The Rose-Waaler test was positive at 
litre I : 1024 Other laboratory findings are listed 
in table I The pathological findings were consist­
ent with the diagnosis of RA In this case there was 
marked hypoalbuminaemia without clinically sig­
nificant proteinuria A roentgenogram of the hands 
showed juxta-articular osteoporosis and narrowing 
of the interosseous joint spaces and small erosions 
at several metacarpophalangeal and proximal in-
terphalangeal joints Disease-modifying therapy was 
started with intramuscular aurothioglucose 50mg 
per week (Auromyose®, Nourypharma, Oss, The 
Netherlands) Oral naproxen 500mg was given twice 
daily in tablets of 250mg (Naprosyne®, Sarva Syn-
tex Nederland, Rijswijk, The Netherlands) Eight 
months after diagnosis major improvement in dis­
ease activity had been achieved At physical exam­
ination the patient had 3 swollen joints, no tender 
joints and no morning stiffness, laboratory findings 
at time of improvement are given in table I 
Methods 
Serum samples were taken for determination of 
naproxen in the third week of treatment and after 
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Fig 1. Naproxen concentration-time curves for total (A) and unbound (B) serum concentrations during long term therapy wrth 500mg 
twice daily in a patient with rheumatoid arthntis at the time of active disease ( · ) and θ months later when major improvement of 
disease activity had been achieved (O) 
8 months of medication with a total dose of 1.5g 
aurothioglucose. The first blood sample was drawn 
immediately before the morning dose of naproxen, 
the next samples at 0.5, 1, 1.5, 2, 3, 4, 8 and 12 
hours; the drug was ingested with breakfast. Freely 
voided unne was collected during this 12-hour pe­
riod. Serum naproxen and unnary naproxen and 
desmelhylnaproxen conjugates were measured by 
high pressure liquid chromatography (HPLC) and 
spectrofluorophotometnc detection (Van Loen-
hout et al. 1982). Unbound naproxen concentra­
tions were determined after equilibrium dialysis 
during 5 5 hours at 37°C against isotonic phos­
phate buffered saline with pH 7 4. The dialysis cell 
contained 1ml serum and 1ml buffer, separated by 
a cellulose dialysis membrane (Cuprophan® 150M) 
Complete absorption of the drug after oral intake 
was assumed for calculation of pharmacokinetics. 
The area under the concentration-time curve dur­
ing the 12-hour dose interval (AUCou) was esti-
ТаЫ· I. Laboratory findings In the patient with rheumatoid arth­
ritis at the time of active disease and 8 months later, when major 
improvement m disease activity had been achieved with auro­
thioglucose therapy 
C-reaclive protein (mg/L 
ESfl (mm/hour) 
Haemoglobin (g/dl) 
Creatinine (fimol/L| 
AST (IU/L) 
Total protein (g/L) 
Albumin (g/L) 
Urinary protein (g/24h) 
Bodyweight (kg) 
Reference 
values 
<-60 
< 2 1 
12-16 
50-90 
< 2 5 
60-80 
37-47 
< 0 10 
Active 
disease 
150 
113 
65 
67 
14 
79 
25 
016 
72 4 
Improve­
ment 
5 6 
32 
123 
75 
13 
71 
41 
015 
73 0 
Abbreviations ESR = erythrocyte sédimentation rate, AST я 
pártate ammo transferase (SGOT) 
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Fig 2 Fraction of unbound naproxen OJ versus the total serum 
naproxen concentrations in a patient with rheumatoid arthritis 
at the time of active disease ( ·) and improvement (O) The fu 
on both occasions shows concentration dependency 
mated according to the linear trapezoidal rule 
Total body clearance (CL) was calculated as dose/ 
AUCo.12 The elimination rate constant (k^,) to de­
scribe the 12-hour interval was obtained from the 
slope of the log-linear regression line through the 
last 3 concentration-time points (i e 4, 8 and 12 
hours post-dose) [elimination half-life, ti/y = 
к.г '-ОбЭЗ] 
The volume of distribution (Vd) was calculated 
from CL/k^i From the values of unbound serum 
naproxen concentrations identical calculations were 
performed to obtain the unbound naproxen phar­
macokinetics AUCo.i2u. CLu, Vd
u
 and ti^ß,, 
Results 
The concentration-time curves for total and un-
bound naproxen are shown in figures ΙЛ and IB, 
respectively, pharmacokinetic parameters are pre­
sented in table II At the lime of improvement the 
serum concentrations of total naproxen were much 
higher than those in the phase of active disease, 
with only minor differences in ti/a, with the un­
bound naproxen concentration only the peak val­
ues were different those in the phase of active dis­
ease being the highest Data on unnarv excretion 
of naproxen metabolites are given in table III The 
recovery of drug metabolites in the unne on the 2 
occasions was similar 
The naproxen fraction unbound (f
u
), both dur­
ing the phase of at tive disease and najor improve­
ment, showed serum drug concentration depend­
ency, the f
u
 observed in each serum sample, as well 
as the least-square lines through the points of the 
respective concentration interval, are shown in fig­
ure 2 Correlation coefTicients were r = 0 80 (p < 
0 01) for active disease and г = 096 (p < 0 001) 
for the time of major improvement, with the as­
sumption of a linear correlation o\ er the range of 
concentrations 
Discussion 
The pharmacological properties and therapeutic 
applications of naproxen [(+)-6-meihoxy-«-methyl-
2-naphthalene-acetic acid] have been reviewed by 
Table II Naproxen pharmacokinetics in the described patient 
during long term therapy with 500mg twice daily Data at the 
time of active disease compared with those at the time of im 
provement 
С (time 0) [mg/L] 
С (time 0) [mg/L] 
С peak (mg/L) 
С peak (mg/L) 
AUCczdng/L-h) 
AUCujHmg/L-h) 
CL (L/h) 
CL,, (L/h) 
Vd(L) 
Vd„ (L) 
ti/a (h) 
tin«, (h) 
Active diseasn 
39 5 
009 
909 
0 73 
699 
2 94 
0 72 
170 
127 
869 
123 
3 5 
Improve 
ment 
79 5 
009 
125 6 
0 32 
1134 
194 
044 
257 
9 0 
1291 
14 1 
3 5 
Abbreviations С • serum concentration С = serum concen 
tration or unbound drug AUG = area under concentration 'ime 
curve CL = clearance Vd * volume of disti Ibution t ^ « elim 
•nation hall life 
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Tab)· III Urinary excretion (mmo1/12h) of naproxen and des 
methylnaproxen conjugates active disease compared witti im 
provement 
Active Improve 
disease ment 
Naproxen conjugates 1 03 0 93 
Desmetnylnaproxen conjugates 0 25 0 33 
Total excretion of naproxen 1 28 (296) 1 26 (289) 
equivalents (mg/12h) 
Brogden et al (1975) Naproxen is highly albumin 
bound, with an fu varying between 0 001 and 0 01 
in the patient described in this report From volun-
teer studies by Runkel et al (1976) it is known that 
naproxen administered in stepwise increased doses 
is subject to increasing metabolism due to its con-
centration-dependent fu, leading to lower-than-ex-
pected rises in AUCO-Œ, At the time of active dis-
ease a higher unbound naproxen peak concentration 
was found in our patient, and an increased CL re-
sulted in a smaller AUC The serum albumin con-
centration in the patient rose markedly, from 25 
g/L at the time of active disease to 41 g/L when 
major improvement in RA had been achieved We 
thus expected to find an alteration in naproxen 
pharmacokinetics more pronounced than in other 
patients with a comparable disease history but less 
striking changes in the serum albumin concentra-
tion It is possible that RA disease activity affects 
not only the serum albumin concentration but also 
the albumin ligand binding per se From the ob-
servations in this case binding characteristics (as-
suming a single class of binding sites) were calcu-
lated (Scatchard 1949) 
At the time of active disease 
Ka = 2 5 ± 0 4 L/ßmol 
(95%CI 1 5-3 5 L/Mmol) 
n = 10 ± 02 (95%CI 0 5-16) 
At the time of improvement 
K.a = 5 4 ± 0 4 І дтоІ 
(95%CI 4 6-6 2 L/Vmol) 
η = 0 9 ± 0 2 (95%CI 0 6-1 3) 
where K
a
 = association constant, η = number of 
binding sites, figures are given as mean ± SD (95% 
Confidence Interval) 
Evidently these association constants are differ­
ent This raises the question whether administra­
tion or endogenous compounds had displaced na­
proxen from the albumin At the time of active 
disease the patient was hospitalised and all drug 
intake was monitored she did not use aspirin or 
any other NSAID Aurothioglucose is not known 
to be a drug displacer of clinical importance Serum 
concentrations of gold dunng aurothioglucose 
therapy are comparable with those reached with 
aurothiomalate 1 to 4 mg/L (Gottlieb et al 1974, 
Van Riel et al 1983) After 40 weeks of aurothio­
glucose therapy. Van Riel and colleagues (from this 
institute) found a mean serum gold concentration 
of 1 5 ± 0 7 mg/L in 10 patients with RA - less 
than 5% of the naproxen concentration on a molar 
base Endogenous compounds able to displace drugs 
from serum proteins in a way comparable to the 
situation in renal failure (Reidenberg & Drayer 
1984), have not been reported in serum of patients 
with active RA The literature concerning modu­
lation of NSAID-protein binding in RA patients is 
scanty and presents conflicting results (Selley et al 
1978, Wanwimolnik et al 1982) Literature on al­
terations in naproxen pharmacokinetics following 
long term administration is not available In this 
case, except for RA disease activity, no variables 
affecting drug kinetics appeared to have changed 
The relative increments of both Vd and CL in 
active disease compared with improvement were 
nearly equal, therefore, t ¡/3ll was less affected Dif-
ferences between t ^ and l]/2au can be explained 
by the alterations of fu over the naproxen concen-
tration range The values of CL,,, given in table II, 
were remarkably high in active disease as well as 
in improvement and exceeded the plasma flow 
through the liver and kidneys together This must 
be due to the fact that naproxen albumin binding 
is not the absolute limiting factor in the drug's me-
tabolism during the passage of albumin-bound drug 
through the liver part of the bound fraction is also 
metabolised We are unable, at present, to provide 
an interpretation of the differences we found be-
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tween CLu in active disease and that in improve­
ment; it is possible that exacerbations in RA affect 
the capacity of the liver to metabolise naproxen. 
The amount of naproxen, and metabolite con­
jugates recovered in the urine during the dose in­
terval (59 and 58% of the ingested dose, respec­
tively) corresponds well with data from volunteers 
given naproxen 500mg twice daily: 57 ± 10% (Up­
ton et al. 1980). In this case, therefore, the bio­
availability of naproxen both in active disease and 
in improvement must have been the same, and it 
may be hypothesised that absorption was nearly 
complete. The unchanged excretion of desmethyl-
naproxen indicates the unaltered pathways of the 
drug's metabolism. These arguments support the 
view that changes in serum albumin cause the 
pharmacokinetic differences described. 
Therapeutic Implications 
The implications of the high unbound concen­
trations of naproxen, as in this patient with active 
RA, are not yet clear. Data on the possible rela­
tionship between the occurrence of side effects and 
high unbound naproxen concentrations are not 
available. To date, the incidence of side effects dur­
ing treatment of patients with active RA has not 
been found to be increased, even at naproxen doses 
up to 1.5g daily (Day et al. 1982). The higher un­
bound drug concentrations, especially in patients 
with more active disease, may even be favourable 
if the anti-inflammatory effects of naproxen cor­
relate with its unbound serum concentration. It has 
to be concluded that, in the case presented, the ef­
fects of RA disease activity on the pharmacokin­
etics of naproxen were impressive. Together with 
a major improvement in the RA, the subject's 
serum albumin concentration rose from 25 to 41 
g/L, resulting in a 30 to 40% decrease in Vd and 
CL; the peak unbound naproxen concentration in 
improvement was only half its level in the active 
disease state. 
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ABSTRACT 
In 9 patients with active rheumatoid a r th r i t i s we studied gastro-
intest inal blood loss during well tolerated therapy with the non-
steroidal anti-inflammatory drug naproxen 500 mg twice dai ly. The 
mean gastrointestinal blood loss, assessed with reinfused autologous 
51cr-labelled erythrocytes, was 1.4 +_ 0.6 ml/day (mean +_ SD) and 
did not exceed the upper normal level . No relationship was observed 
between individual gastrointestinal blood loss and serum concentra-
tions of protein-unbound or total naproxen, or the duration of drug 
treatment, or the degree of disease ac t iv i ty of rheumatoid a r t h r i t i s . 
Two subjects developed peptic ulcer disease after the study, in which 
they had a blood loss of 0.9 and 1.9 ml/day, respectively. 
INTRODUCTION 
Adverse drug reactions, originating from the gastrointestinal t rac t , 
constitute the major part of problems with non-steroidal ant i -
inflammatory drug (NSAID) therapy for j o i n t diseases. The di f ferent 
NSAIDs have an inh ib i t ion of prostaglandin synthesis in common, and 
gastrointestinal mucosal lesions seem to be inevitably linked with 
th is pharmacological action. We studied naproxen, a highly albumin-
bound NSAID, frequently used for the symptomatic treatment of 
rheumatoid a r t h r i t i s . Protein-unbound serum naproxen concentrations 
were found elevated, due to disease-associated hypoalbuminaemia in 
patients with rheumatoid a r th r i t i s and active polyarticular 
inflammation, either in comparison with healthy young volunteers (1) 
or within the same patient at a moment that major improvement in 
disease ac t iv i ty had been achieved (2). I t can be hypothesized that 
gastrointestinal damage is related with the protein-unbound drug 
concentration, so the observation of higher unbound drug 
concentrations in patients with active rheumatoid j o in t inflammation 
prompted us to study the possib i l i ty of increased gastrointestinal 
lesions in that phase of disease during naproxen therapy. Tlierefore 
we measured gastrointestinal blood loss, using the method of 
reinfused ^Icr- label led erythrocytes. 
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PATIENTS AND METHODS 
Subsequent patients with classic or def in i te rheumatoid a r t h r i t i s 
according to the c r i t e r i a of the Anerican Rheumatism Association ( 3 ) , 
hospitalized in view of active disease, were invited to enter the 
study i f naproxen therapy was continued or was i n i t i a t e d on admission 
by the caring physician. Nine patients, 5 women and 4 men, aged 54+8 
years (mean ± SD) entered the study. The c l i n i c a l and laboratory 
findings in these patients are presented in Table I . For each patient 
an index of disease act iv i ty (4) was assessed; i t was calculated by 
grading on a 4-point scale the haemoglobin concentration, the 
erythrocyte sedimentation rate according to the Westergren method, 
the number of tender j o i n t s and the duration of morning s t i f f n e s s ; 
the total was then divided by four. In a l l patients the anaemia was 
diagnosed as anaemia of chronic disorders (5). None had abdominal 
discomfort or ulcer complaints from the start of naproxen treatment 
unt i l the end of the study. Two female patients had a history of 
ulcer disease. Al l patients received disease modifying drug 
treatment: 50 mg intramuscular aurothioglucose weekly (n=3), 100 mg 
oral azathioprine daily (n=2), 100 mg oral azathioprine plus 
prednisone 5, 7.5 and 10 mq dai ly respectively (n=3), 500 mg oral 
d-penicillamine dai ly (n=l) . All patients used oral naproxen at a 
dosage of 500 mg twice daily at least 5 days before 51ο label l ing 
of erythrocytes. 
^ C r label l ing of autologous erythrocytes was performed using 
standard Nuclear Medicine techniques (6). Venous blood was drawn and 
collected in ACD-A anticoagulant. After removal of plasma, 50 μΟΙ 
1.85 MBq) Na251Cr0i4 in 0.9% NaCl was added; the mixture was 
incubated at 37° С for 15 minutes. The labelled red cel ls were washed 
twice in 0.9% NaCl before intravenous reinfusion. On each of the next 
7 days a venous blood sample was drawn to determine ^ C r radio­
a c t i v i t y . From the moment of reinfusion on, the total amount of 
stools was col lected. On the 7th day after reinfusion 2 g oral 
carmine was administered and stool col lect ion continued unt i l the 
f i r s t appearance of red-coloured faeces to correct for individual 
bowel t rans i t time. After completion of the stool col lect ion the 
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TABLE I. CLINICAL AND LABORATORY DATA IN NINE PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA) 
Patient/ Duration Duration Concomitant Hgb ESR Morning Number of IDA 
sex/age of RA of naproxen medication* st i f fness tender 
use jo in ts 
years days nmol/1 mm/h hours points 
l/F/52 
2/M/49 
3/F/41 
4/F/56 
5/M/60 
6/F/65 
7/F/61 
8/M/59 
9/M/47 
15 
0.3 
19 
0.2 
7 
0.2 
1 
0.2 
14 
28 
22 
12 
49 
40 
17 
13 
21 
16 
3 
1 
2,4 
1 
2 
2 
2.4 
1 
2.4 
6.9 
8.1 
6.3 
6.6 
7.7 
6.2 
5.3 
5.8 
7.1 
42 
55 
72 
70 
22 
65 
81 
7 
67 
2 
1 
4 
1.5 
0.5 
2 
2.5 
2 
0 
6 
10 
24 
19 
25 
5 
30 
4 
4 
2.25 
2.75 
3.5 
3.25 
2.75 
2.75 
3.75 
2.5 
2.25 
•Concomitant medication: 1 = aurothioglucose; 2 » azathioprine; 3 = d-pencillamine; 
4 » prednisone. 
Hgb = haemoglobin concentration, reference values: F: 7.5-10.0 ; M: 8.5-11.0 nmol/l 
ESR = erythrocyte sedimentation rate, reference values: F: < 21 ; M: < 10 imi/h 
IDA » Index of disease ac t i v i t y . 
faecal 51ο radioact iv i ty was counted in a geometrically 
independent whole body counter. The mean gastrointestinal loss of 
blood in ml/day was calculated from the mean faecal rad ioact iv i ty 
excreted per day, divided by the mean blood radioact iv i ty per ml. The 
tota l body radiation dose from the infused S^ -Cr was estimated as 
approximately 0.74 тгет/цСі (0.21mSv/MBq) (7). 
Total and unbound naproxen concentrations were determined during one 
dose interval of 12 hours. Serum samples were taken at time 0 and at 
0.5, 1, 1.5, 2, 3, 4, 8 and 12 hours after the morning dose of the 
drug. Naproxen was measured with HPLC and spectrofluori photometric 
detection (8). The unbound drug concentration was determined after 
equilibrium d ia lys is . The peak concentration (Cpeak) was the 
highest concentration observed; the average concentration (C a v ) 
was calculated from the area under the concentration-time curve, 
estimated with regard to the linear trapezoidal r u l e . 
STATISTICAL ANALYSIS 
Spearman's rank correlation was used to analyse for s ignif icant 
relationship between parameters. 
STUDY ETHICS 
The study was approved by the Ethics Committee of the University 
Hospital St Radboud and was performed in accordance with the 
principles laid down in the Declaration of Helsinki. Patients had 
given verbal informed consent. 
RESULTS 
In al l subjects a complete stool col lection allowed measurement of 
the gastrointestinal blood loss over a 7-day period. The mean dai ly 
faecal blood loss of the 9 patients with active rheumatoid a r t h r i t i s 
was: 1.4 ± 0.6 ml (mean ± SD). The median of the dai ly blood loss was 
1.1 ml. The individual mean dai ly gastrointestinal blood loss was not 
correlated with either the Cpeak 0 Γ w i t h t h e ^av o f serum unbound 
and tota l naproxen; Table I I gives the individual data. 
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TABLE I I . GASTROINTESTINAL BLOOD LOSS AND PROTEIN-UNBOUND AND 
TOTAL DRUG CONCENTRATIONS IN PATIENTS WITH ACTIVE 
RHEUMATOID ARTHRITIS DURING TREATMENT WITH 500 mg 
ORAL NAPROXEN TWICE DAILY 
P a t i e n t s Mean Cpeak C a v C p e a k C a v 
blood loss unbound unbound t o t a l t o t a l 
ml/day μς/Ι μ9/1 mg/l mg/l 
1 
2 
3 
4 
5 
б 
7 
8 
9 
0.6 
0.8 
0.9 
0.9 
1.1 
1.9 
2.0 
2.1 
2.1 
202 
109 
126 
415 
175 
403 
547 
129 
206 
77 
45 
70 
80 
74 
151 
182 
60 
74 
ПО 
70 
85 
103 
83 
83 
86 
91 
90 
74 
42 
66 
51 
55 
58 
61 
62 
49 
The individual mean dai ly gastrointestinal blood loss obviously 
showed no relationship with the duration of exposure to the naproxen 
regimen of 1 g dai ly before 51çr label l ing of red cells was 
performed, nor with the interval between the diagnosis of rheunatoid 
a r th r i t i s and the performance of th is study. Furthermore, no 
relationship was found between the mean dai ly faecal blood loss and 
the assessed index of disease act iv i ty . Individual results are 
presented in the Figure. 
DISCUSSION 
Since the well-documented study of Stubbé (9) i t has been known that , 
during treatment of rheumatoid a r th r i t i s with acetyl-sal icyl ic acid, 
faecal blood loss is detectable with the benzidine reaction in 70% of 
the patients; in that study a posit ive benzidine reaction 
corresponded with a dai ly loss of 4 ml blood or more. Later Leonards 
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С г gastrointestinal blood loss 
2.0-
1.6-
1.2-
0.8-
0.4-
L A n 1 1 1 1 ' 
2.0 2.5 3.0 3.5 4.0 
index of disease a c t i v i t y (points) 
FIGURE. 
Mean dai ly gastrointestinal blood loss determined after reinfusion of 
5lCr-labelled erythrocytes in 9 patients with active rheunatoid 
a r t h r i t i s , during treatment with 500 mg oral naproxen twice d a i l y , 
plotted against the index of disease a c t i v i t y . 
et a l . (10) observed in volunteers, given aspirin 3.6-4.5 g d a i l y 
over a 28 day period a mean gastrointestinal blood loss, measured 
with autologous 5 lCr-label led erythrocytes, of 3.6 ± 2.2 ml/day. 
Naproxen, in comparison with aspirin has been reported to cause a 
s ign i f icant ly smaller gastrointestinal blood loss in rheumatoid 
a r t h r i t i s patients (11). With regard to the results of previous 
51cr-labelled red cel l studies with volunteers and out-patients 
during naproxen administration, l isted in Table I I I , the amount of 
gastrointestinal blood loss in our study is 1n the same order of 
magnitude. We compared our findings with data from l i t e r a t u r e , 
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TABLE I I I . DATA ON GASTROINTESTINAL BLOOD LOSS, MEASURED WITH 51cr-
LABELLED ERYTRHOCYTES FROM PATIENT AND VOLUNTEER STUDIES 
Reference Number o f Pat ients/ D a i l y Gastro-
s u b j e c t s Volunteers naproxen intest inal 
dosage blood loss* 
(mg) (Mean+S.D.) 
Lussier et a l . (12) 6 
Magnussen et a l . (13) 12 
Lussier et a l . (11) б 
Salom et a l . (14) 9 
This study 9 
V 
ν 
Ρ 
ν 
Ρ 
500 
500 
750 
750 
1000 
1.5 + 0.6 
2.0 + 1.9 
1.0 + 0.5 
1.2 + ? 
1.4 + 0.6 
•Results are presented in ml/day, except for reference 11, where 
gastrointestinal blood loss is given in ml/sample of faeces. 
because i t was judged unethical to withdraw NSAID treatment from our 
patients with active polyarticular inflammation for a s u f f i c i e n t l y 
long period to make an assessment of the individual baseline faecal 
excretion of 51ο r a d i o a c t i v i t y . Both the mean (1.4 ml/day) and the 
median (1.1 ml/day) gastrointestinal blood loss in our 9 patients 
with active rheumatoid a r t h r i t i s is below the upper normal level of 
faecal excretion of 51ς
Γ
_labelled, reinfused autologous erythro­
cytes: 1.5 ml/day (mean + 2 χ SD from 148 subjects) (15). 
In man, the presence of rheumatoid a r t h r i t i s per se has never been 
shown to aggravate NSAID-induced gastrointestinal mucosal lesions; 
t h i s in contrast with polyarthr i t ic animals showing more gastric 
bleeding than controls (16). The gastroscopie f inding of more mucosal 
lesions during a one week regimen of 750 mg naproxen d a i l y , in 
comparison with 500 mg daily in the preceding week (17), suggests the 
existence of a dose- or concentration-effect relationship for gastro­
intest inal damage. A volunteer study of ^ C r faecal blood loss 
during long-term administration of 20 mg Piroxicam dai ly , showed an 
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increase in gastrointestinal blood loss with time, unt i l after the 
second week of Piroxicam administration a steady state serun level 
was achieved (18). This points to either a certain period of time 
needed to produce 51cr loss by mucosal lesions, or a concentration-
effect relat ionship. In our study, a l l patients started to use 
naproxen at least f ive days before the study; so suff ic ient time to 
reach stable pre-dose concentrations had elapsed. For a highly 
protein-bound drug (naproxen albimin binding exceeds 99%) the unbound 
serum concentration is a more meaningful value to study drug 
pharmaco-dynamics; both the peak and average serun concentrations of 
unbound naproxen were therefore analysed for a possible correlat ion 
with the individual gastrointestinal blood loss of the patients. 
Taking together the results of th is and of the previous studies 
(11-14), the amount of gastrointestinal blood loss, measured with 
SlCr red c e l l s , f a i l s to show an evident dose or concentration 
dependency during treatment of volunteers and rheumatoid a r t h r i t i s 
patients with naproxen in the dose range 0.5-1 g d a i l y . 
In two women (patients 3 and 6) peptic ulcer disease developed one 
and four weeks after f inishing the study. Both had a history of 
peptic ulcer disease in the past: in patient 3 in association with 
the use of indomethacin and in patient б unrelated with NSAID 
therapy. Patient 3 presented with complaints of typical abdominal 
pain on the 20th day of naproxen administration; endoscopic 
examination revealed a small superficial pyloric ulcer and mult iple 
mucosal lesions in the duodenal bulb. Patient 6 presented at the 50th 
day of naproxen administration with sudden appearance of tar-coloured 
stools preceded by vague complaints of a short duration; endoscopy 
showed a bleeding gastric ulcer at the lesser curvature. Anaemia had 
worsened from a haemoglobin concentration of 6.2 to 4.1 mmol/1. 
We conclude t h a t , although the number of observations is l i m i t e d , 
that patients suffering from the most active rheumatoid a r t h r i t i s did 
not show the largest gastrointestinal blood loss. In the majority of 
the patients with active rheumatoid a r t h r i t i s the blood loss was well 
below the upper normal level; the amount of gastrointestinal blood 
loss in the patients was not related to the duration of naproxen 
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treatment. Therefore, i f pathological faecal blood loss is observed 
in patients with active rheumatoid a r t h r i t i s during naproxen therapy, 
th is is most l i k e l y due to other, individual causes and merits 
careful diagnostic investigation; c l in ica l data support this view 
(19). F inal ly, individual patients evidently develop peptic ulcer 
disease without a preceding gastrointestinal blood loss of major 
c l i n i c a l importance. The absence of a more than expected 51ο loss 
has no predictive value for ulceroqenesis. 
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CHAPTER VII 
CONGESTIVE HEART FAILURE DUE TO NON-STEROIDAL 
ANTI-INFLAMMATORY DRUGS IN THE ELDERLY 
FA van den Ouwel and, FWJ Gn'bnau and RHB Meyboom 
Age Ageing (accepted for publication) 
NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AS A 
PROGNOSTIC FACTOR IN ACUTE PULMONARY EDEMA 
FA van den Ouwel and and FWJ Gribnau 
Arch Intern Med 1987; 147; 176-179 
(with permission of the editor) 
SUMMARY 
Congestive heart f a i l u r e poss ib ly due to treatment wi th non-stero ida l 
ant i - in f lammatory drugs in the e lder l y was studied by means of a 
quest ionnaire to the pa r t i c ipan ts of a postgraduate course on 
locomotor diseases in the e l d e r l y , and by analysis of the hospi ta l 
records of 600 e l d e r l y subjects diagnosed wi th congestive heart 
f a i l u r e . The quest ionnaire revealed 22 possib le cases, reported by 20 
physicians (84 physic ians out of 243 responded the quest ionna i re) . 
In the hosp i ta l populat ion 5 probable cases were detected. Deta i ls of 
these pa t ien ts are presented. In contrast wi th f ind ings in 
l i t e r a t u r e , in no case was solute re ten t i on the resu l t of kidney 
func t ion impairment. 
The spec i f i c problems regarding the a t t r i b u t a b i l i t y of t h i s adverse 
e f f e c t are discussed. The resu l t s of our study give fu r the r evidence 
tha t congestive heart f a i l u r e due to non-s tero ida l ant i - in f lammatory 
drug treatment i s a probable adverse drug react ion in e l d e r l y 
i nd i v idua ls wi th or wi thout a h i s t o r y o f impaired cardiac 
performance. I t may r e s u l t from drug t o x i c i t y fo l l ow ing ( r e l a t i v e ) 
overdosing in t h i s age group, from reduced ef fect iveness of 
concomitant d i u r e t i c treatment or from e f f ec t s on cardiovascular 
homoeostasis. 
INTRODUCTION 
The incidence of locomotor diseases increases throughout l i f e and so 
does drug use fo r i t s t rea tment l . The occurrence of water and sa l t 
r e t e n t i o n , as wel l as resistance to d i u r e t i c s , has been reported as a 
s ide e f fec t of non-s tero ida l ant i - in f lammatory drugs (NSAID)2-5 and 
occas iona l ly t h i s may resu l t in congestive heart f a i l u r e (CHF)6. 70 
assess CHF as a side e f f ec t of NSAID therapy in the e l d e r l y , we asked 
general p r a c t i t i o n e r s and nursing home physicians whether they-had 
not iced possib le cases and we also performed a re t rospec t i ve study in 
the pat ient populat ion of the Univers i ty Hospital St Radboud. 
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METHODS 
Study part I: we sent a questionnaire to the participants of a local 
postgraduate course on locomotor diseases in the elderly to collect 
their cases suggesting CHF during NSAID treatment. We asked the 
participants whether such a case had ever been noticed by them and, 
if so, to provide details about this patient on a structured answer 
form. If respondents reported never to have seen this side effect, we 
asked to indicate this; we also asked whether they were familiar with 
the possibility of CHF induced by NSAID. The subject had been 
mentioned, but not with particular emphasis, during the preceding 
course; the mailing of the questionnaire had not been announced. 
Study part II: in retrospect the medical records of 600 patients from 
the Department of Internal Medicine and Cardiology, diagnosed as CHF 
within the five-year period 1981-1985, were screened for concomitant 
locomotor diseases, being the main indication for NSAID prescription. 
Diagnoses in this hospital are classified according to the 9th 
Clinical Modification of the International Classification of 
Diseases7 (ICD-9-CM). CHF had been diagnosed if at least one 
episode of left or right ventricular failure^ had occurred; 
concomitant locomotor disease comprised the diagnoses 710-739 and 
diagnosis 274 according to ICD-9-CM. Kidney function was assessed 
with the aid of a nomogran using serum creatinine, body weight, age 
and gender as variables^. 
RESULTS 
Physicians' questionnaire (Study part I): 243 forms were mailed three 
weeks after the postgraduate course; 84 {35%) were returned. The 84 
respondents are listed according to their professional status in 
Table 1. Of the respondents, 20 reported having observed one or more 
patients with CHF after starting NSAID therapy, resulting in a total 
number of 22. In 5 patients the event took place less than one month, 
and in four between one and eight months before the questionnaire was 
mailed; another 13 patients were reported with CHF occurring more 
than one year before this study. Of the responding physicians not 
reporting a case, 48% were faniliar with CHF as an adverse effect of 
NSAID therapy. 
71 
participât! 
physicians 
η (*) 
150 (62) 
64 (26) 
11 (4.5) 
7 (3) 
11 (4.5) 
ng respond ing 
physicians 
η 
46 
32 
4 
1 
1 
physicians 
observing CHF 
η 
11 
8 
1 
0 
0 
TABLE I. PROFESSIONAL STATUS OF PHYSICIANS RECEIVING THE 
QUESTIONNAIRE ON CHF DUE TO NSAID THERAPY AND OF THE 
RESPONDENTS 
Professional status 
of the physicians 
general practitioners 
nursing home physicians 
internists 
geriatricians 
physicians in training 
Twenty-two patients were reported, but only 13 cases could be 
documented in detail (Table II). These 13 patients were aged 
8l!:9 years (meantSD); there were 11 females and 2 males; 9 of the 13 
definitely had suffered from heart failure at least once before. The 
other four patients were not known with this diagnosis to their 
physician; however, all four used diuretic therapy. The time interval 
between the start of NSAID treatment and the diagnosis of CHF in the 
13 cases ranged from 2 days to several years, but the median time 
interval was one month. 
Patient record analysis (Study part II): the medical records of 600 
patients with CHF were screened for the existence of concomitant 
locomotor diseases. Of the 58 patients with such a combination of 
diagnoses, 22 had been treated with a NSAID at the time of heart 
failure. The indications to prescribe a NSAID were: osteoarthritis 
(n=10), rheumatoid arthritis (n=9), polymyalgia rheumatica (n=l), 
gouty arthritis (n=l) and hypertrophic osteoarthropathy (n=l). The 22 
patients had a mean age of 77+5 years, there were 16 females and 
6 males. The mean creatinine clearance at the time of CHF was: 
56i:19 ml/min. Apart from CHF, other clinically important diagnoses in 
these 22 patients were: atrial rhythm disturbances (atrial 
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fibrillation, flutter and sick sinus syndrome) (n=13), myocardial 
infarction in the history (n=9), angina pectoris (n=9), diabetes 
mellitus (n=7), hypertension (n=6), chronic obstructive lung disease 
(n=4), peptic ulcer disease in the history (n=3), valvular heart 
disease (n=2), bronchial carcinoma (n=l). 
In the group of 22 CHF patients, 7 used NSAID chronically and for 2 
patients the duration of therapy had not been recorded. The median 
time interval between CHF and the start of NSAID treatment was 2 
months. 
In 17 of 22 cases a probable cause, not primarily NSAID related, to 
explain the occurrence of CHF was determined: onset of atrial 
fibrillation or flutter (n=7), echocardiographically confirmed 
congestive cardiomyopathy existed in 3 of these cases; cessation of 
diuretics or failure to comply with the medication (n=5) or with 
dietary salt restriction (n=4); myocardial infarction complicated by 
CHF occurred in 3 patients; three patients with chronic obstructive 
lung disease experienced CHF at the time of an exacerbation; one 
patient suffered acute pulmonary edema twice within a short period 
due to aortic regurgitation with coexistent aortic stenosis. 
Drugs prescribed to the 17 patients were: indomethacin (n=7), 
Ibuprofen (n=5), diclofenac sodium (n=2), fenoprofen (n=l), naproxen 
(n=l), Piroxicam (n=l). 
In the remaining 5 cases the occurrence of CHF could be judged due to 
NSAID treatment: no other precipitant was found. Of these patients 4 
had had indomethacin treatment and 1 patient diclofenac sodium. 
Details on these patients are listed in Table III*: the mean age was 
77±4 years, there were 3 females and 2 males. The mean creatinine 
clearance was 76+15 ml/min. Four patients previously had no apparent 
heart disease; one patient with a moderately compromised cardiac 
status needed diuretic treatment with 40 mg furosemide daily. This 
patient had chronic atrial fibrillation; all other patients had a 
regular sinus rhythm at electrocardiography. 
* Table III is presented at page 86 (reference 30) 
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TABLE I I . DETAILS OF 13 PATIENTS WITH CHF SUSPECTED TO BE DUE TO THE USE OF NSAID, OBSERVED BY THE 
PHYSICIANS RETURNING THE QUESTIONNAIRE 
Age/sex NSAID, dosage time i n t e r v a l concomitant d i u r e t i c f i n d i n g s of 
mg/day medication CHF 
special remarks 
81 
94 
76 
71 
74 
85 
80 
82 M 
oxyphenbutazone 
3 χ 100 p.o. 
diclofenac sodium 
3 χ 25 p.o. 
phenylbutazone 
indomethacin 
Ibuprofen 
diclofenac sodium 
3 χ 50 p.o. 
indomethacin 
4 χ 25 p.o. 
naproxen supp. 
5 χ 500 p.o. 
Ibuprofen 
3 χ 400 p.o. 
naproxen 
2 χ 250 p.o. 
2 days 
some days 
some days 
10 days 
12 days 
14 days 
1 month 
1 month 
chlortalidone 
furosemide 
furosemide 
furosemide 
diuretics not 
specified 
pedal oedema, 
dyspnoea 
pedal oedema, 
r a l e s 
pedal oedema 
a f t e r a l l three 
NSAID's 
pedal oedema 
dyspnoea, r a l e s , 
distended j u g u l a r 
v e i n s , oedema 
general oedema, 
r a l e s 
dyspnoea, 
r a l e s 
dyspnoea, r a l e s , 
distended j u g u l a r 
v e i n s , oedema 
no CHF known, 
hypertension 
no CHF known 
CHF in the past 
no CHF known 
CHF in the p a s t , 
concomitant 
pneumonia 
no CHF known, 
thyroid carcinoma 
with metastases 
CHF in the past 
sick sinus syndrome 
a t h e r o s c l e r o s i s , 
CHF in the past 
63 F ibuprofen 1.5 month 
3 χ 400 p.o. 
90 F indomethacin supp. 2 months 
50 mg once the 
other day 
89 F ibuprofen 3 months 
3 χ 400 p.o. 
87 M piroxican 5 months 
1 χ 20 p.o. 
79 F naproxen years 
3 χ 250 p.o. 
acute pulmonary CHF in the past, 
oedema atrial fibrillation 
furosemide pedal oedema, CHF in the past 
dyspnoea, 
rales 
diuretics not pedal oedema. Chest X-ray: CHF, 
specified dyspnoea. Weight gain 3 kg, 
rales CHF in the past 
dyspnoea. CHF in the past, 
rales atrial fibrillation 
cor pulmonale 
furosemide CHF in the past, 
Spironolacton atrial fibrillation 
DISCUSSION 
Study parts I and II are both retrospective analyses; inevitably the 
results are subject to bias due to methodological factors. In Study 
part I (the questionnaire to general practitioners and nursing home 
physicians) the information was obtained from a small group of 
responders. Approximately half the responders were familiar with CHF 
as a side effect of NSAID in the elderly. 
In 9 of the 22 reported patients the event had taken place in the 
preceding 8 months. This may indicate a more common occurrence of 
NSAID-induced CHF if only the most recent patient was recalled by a 
few physicians, and other cases passed by unnoticed or were 
forgotten. 
The subjects drawn from the hospital patient population (Study part 
II) probably do not represent a random sample of CHF patients in the 
community, but very likely form a group of elderly patients with more 
complex medical histories. Moreover collecting reliable and 
comprehensive data on drug intake often is difficult. It may be 
assumed that the number of patients within the hospital population 
listed with CHF and locomotor diseases was complete; however, the 
underreporting of NSAID medication in the patient records remains a 
problem, the more so since these drugs are commonly prescribed as 
analgesics. 
The seven different NSAID administered to the patients of Study 
part I most likely represent the respondents' prescription preference 
among the numerous NSAID available today. In Study part II, NSAID-
induced C4F is most often related to indomethacin treatment. This may 
be explained by the fact that indomethacin was the most prescribed 
NSAID for patients with rheumatoid arthritis in this hospitallO at 
the time of the study. 
Although drugs may differ in safety in this respect, CHF during NSAID 
treatment in the elderly may well be an inherent side effect of this 
class of drugs. It has been generally accepted that the NSAID, 
derivatives of a number of chemically unrelated compounds, have in 
common an inhibitory effect on cyclooxygenase. This is the key enzyme 
in the biosynthesis of prostaglandins and thromboxanes from 
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arachidonic acid. Most of the therapeutic actions and side effects of 
the various NSAID are similar and related to the inhib i t ion of 
prostaglandin synthesis!!. 
Two of the described cases of CHF during NSAID treatment in the 
elderly seem to be dose related. Drug tox i c i t y may have precipitated 
acute pulmonary oedema in one female patient of the hospital 
population group, who exceeded the recommended dai ly dosage of 150 mg 
diclofenac sodium by taking 200 mg during 60 days. In the group of 
patients in Study part I , one took 2500 mq naproxen dai ly . In the 
elder ly, half the adult dosage has been advisedl2. Apart from the 
existence of persons with a high r isk characteristic i t is possible 
that apparently healthy elderly individuals, due to age related 
factors per se, are more l iab le to suffer from a side ef fect , i . e . 
CHF during NSAID treatment. 
Advanced age is a r isk factor for acute renal deterioration caused by 
NSAID treatment^, 14. The influence of NSAID on the kidney function 
is generally only modest and the majority of the pharmacodynamic 
effects observed during 3-4 days of NSAID usel5,16 disappear after 
prolonged adinim'strationl7-20 t No case of acute renal fa i lu re has 
been diagnosed in the patients with CHF in our study. However, data 
on the exact kidney function of the subjects reported by the 
physicians' questionnaire obviously cannot be given. The f ive 
patients of Study part I I a l l had a normal or even above-averaqe 
kidney function for their age at the time of diagnosis. Thus NSAID-
induced renal fa i lu re cannot explain the solute retention in any of 
these patients. 
Eiqht of the thirteen patients of the physicians' questionnaire and 
one of the patients in Study part I I were known with CHF in the 
past. We do not have an estimate of the degree of heart fa i lure for 
the majority of these. From the study of Dzau et al.21 i t is known 
that patients of al l ages with severe heart fa i lure and a serum 
sodium concentration below 135 mmol/1 show a signif icant decrease in 
cardiac index and an increase in l e f t ventricular end-diastolic 
pressure, mean ar ter ia l pressure and systemic vascular resistance 
when challenged with oral indomethacin. Further, some evidence is 
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available that prostaglandin metabolites and thromboxanes influence 
the coronary c i rculat ion of patients with heart disease^.ZS^ but 
at th is moment there is no proof that NSAID exert a negative 
inotropic effect on the heart muscle, be i t insuff ic ient or not. I t 
remains a poss ib i l i ty that in some of our patients with a compromised 
cardiac status, and thus c r i t i c a l l y dependent on prostaglandin-
mediated vasodilation, the mechanism of CHF was the NSAID-induced 
imbalance of c i rculatory homoeostasis. 
Final ly four of the thirteen patients in Study part I and one of the 
f ive in Study part I I had furosemide treatment. NSAID blunt the 
diuret ic response to furosemide5,24# i n these patients solute 
retention and congestive heart fa i lu re are readily explained by a 
decreased furosemide e f fec t . 
Peripheral oedema soon after the start of medication has been 
reported as an adverse effect of NSAID in 0-35% of the pa t ien ts^ . 
The responsible NSAID action possibly is an increase in chloride and 
sodium retention by the kidney at the si te of the medullary segment 
of the thick ascending limb of Henle's loop26. This phenomenon 
obviously does not explain the precipi tat ion of CHF in the majority 
of the elderly subjects described. One can only speculate about the 
fact that , or why patients with a previously unnoticed or c l i n i ca l l y 
s t i l l undetectable degree of heart fa i lu re need an individual ly 
variable period of time before the symptoms of CHF ensue: the time 
interval between the start of drug administration and the occurrence 
of CHF varied between a few days and six months or more of continuous 
treatment with NSAID. The median time interval in the 13 patients of 
Study part I was one month, and that in the 22 patients of Study 
part I I was 2 months. Therefore, no straightforward time-event 
relationship was abvious in the majority of the patients and this is 
one of the d i f f i c u l t i e s in assessing CHF as an adverse effect of 
NSAID treatment. A further approach to judge the apparent CHF as a 
possible side effect is to observe dechallenge: disappearance of 
symptoms after withdrawal of the suspected drug. This is not 
rea l i s t i c in CHF, because, together with NSAID cessation, the 
introduction of other therapeutic interventions (e.g. bed rest , 
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dietary salt r e s t r i c t i o n , oxygen, diuret ics and other medication) is 
appropriate. Rechallenge, re-administration of the suspected drug, 
often cannot be performed under identical conditions. Classic 
a l g o r i t h m s ' 7 - ^ f o r judging suspected adverse drug reactions use 
time-effect relat ionship, dechallenge and rechallenge as evidence. 
Assessment of NSAID-related CHF in the elderly patients of th is study 
with such methods consequently results in a r e l a t i v e l y low score of 
prob ab i l i t y . 
Our data confirm that CHF does occur, and presumably more often than 
the paucity of reports in l i t e r a t u r e would suggest, as a probable 
complication of NSAID treatment in the elder ly. Patients with 
previous CHF or diuret ic treatment are more at r isk for NSAID-induced 
CHF, but the adverse effect also strikes elderly subjects with a 
hitherto uncompromised cardiac status. In contrast to earl ier reports 
we did not f ind renal insufficiency in our patients. In some cases 
CHF is associated with a relat ive or absolute overdose. 
Supposed that NSAID were causally involved in our patients, classic 
methods to evaluate side effects of drugs f a i l in th is retrospective 
assessment for two main reasons: there is an unpredictable and 
sometimes long time interval between the start of treatment and the 
onset of symptoms, and the observation of dechallenge and rechallenge 
is often impossible. The retrospective nature of our study does not 
allow a firm conclusion either about the incidence of CHF as a 
complication due to NSAID treatment in the elderly or about the 
safety of one or more of the di f ferent NSAID in part icular. 
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We read with interest the article by Goldberger et al. that was 
published in the March 1986 issue of the Archives^. In 106 
admissions, the precipitant factor of acute pulmonary edema and the 
outcome of the illness have been studied by chart review and either 
telephone contact with the patients or analysis of questionnaires 
mailed to patients who could not be reached by telephone. Details of 
the patient's medical history and preadmission medication were 
presented, but therapy with nonsteroidal anti-inflammatory drugs 
(NSAIDs) was not specifically mentioned. Occasionally, therapy with 
NSAIDs induces congestive heart failure by solute retention2t or by 
blunting the diuretic response to furosemide therapy^. Today, NSAID 
therapy is administered widely to an impressive part of the elderly 
population^»5. 
We screened the records of 600 patients with congestive heart 
failure, consecutively admitted to the Department of Medicine of our 
hospital, in an attempt to find cases of congestive heart failure 
attributable to treatment with NSAIDs. Twenty-two patients were 
treated with NSAIDs at the moment of admission, because of previously 
diagnosed osteoarthritis (n=9), polymyalgia rheumatica (n=l), gout 
(n=l) and hypertrophic osteoarthropathy (n=l). The most likely cause 
or combination of causes to explain the occurrence of congestive 
heart failure could be determined in 17 of 22 patients, and these 
comprised the following: the onset of atrial fibrillation or flutter 
(25%), cessation or failure to comply with diuretic therapy (21%) or 
dietary salt restriction (14%), myocardial infarction (11%), 
progessive worsening of congestive cardiomyopathy (11%), lower airway 
infection in patients with chronic obstructive lung disease (11%), 
and valvular heart disease (7%). Concomitant use of therapy with 
NSAIDs had been initiated two or four weeks before the event (n=5) or 
had been going on for a much longer time (n=12). 
Five cases of congestive heart failure were observed without any 
precipitant save the recent initiation of therapy with NSAIDs; 
details are listed in the Table. One patient (1) presented with the 
signs of acute pulmonary edema, and four other patients presented 
with lower leq edema, distended jugular veins, and weight gain. Only 
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one patient (4) had a moderately compromised cardiac status for which 
treatment with furosemide had been previously prescribed. All 
patients had normal kidney functions for their age at the onset of 
the event. 
I t must be noted here that indomethacin has been the most frequently 
prescribed NSAID in our hospita l 6 . This can explain why one 
particular drug may have provoked the four cases of congestive heart 
fa i lure due to therapy with NSAIDs, but i t is possible that the 
various NSAID regimens d i f f e r in safety in th is respect. 
We, therefore, conclude that congestive heart f a i l u r e as well as 
acute pulmonary edema can be precipitated by treatment with NSAIDs in 
elderly patients with an uncompromised cardiac status. Although 
NSAID-induced acute pulmonary edema is a rare event, we wonder i f any 
of the patients in the study of Goldberger et a l . could have 
experienced th is side effect. If i t is possible to withdraw the 
particular mode of therapy in such a case, we expect the prognosis of 
the patient to be ameliorated. 
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TABLE. DETAILS OF FIVE CASES OF CONGESTIVE HEART FAILURE, PROBABLY DUE TO NSAID TREATMENT, OBSERVED IN A STUDY OF 
600 ADMISSIONS* 
Age/sex 
1/76/F 
2/80/F 
3/82/F 
4/71/M 
5/74/M 
Creat in ine 
clearance 
ml/min 
(ml /s) 
60 
(1) 
100 
(1.67) 
80 
(1.33) 
70 
(1.17) 
70 
(1.17) 
NSAIO 
formulat ion 
dic lofenac sodium, 
sustained release 
indomethacin 
indomethacin, 
supposi tory 
indomethacin 
indomethacin, 
supposi tory 
Dose 
mg/day 
, 200 
75 
100 
50 
100 
Star t of NSAID 
t reatment , 
days before 
congestive 
heart f a i l u r e 
-60 
-21 
-80 
-60 
-3 
Ind ica t ion 
rheumatoid 
a r t h r i t i s 
polymyalgia 
rheumatica 
rheumatoid 
a r t h r i t i s 
o s t e o a r t h r i t i s 
o s t e o a r t h r i t i s 
Findings at 
admission 
Acute pulmonary 
edema 
pedal edema, 
elevated jugu lar 
venous pressure 
pedal edema, 
elevated jugu la r 
venous pressure 
pedeal edema, 
elevated jugul ar 
venous pressure 
pedal edema, 
elevated jugu la r 
venous pressure 
Body weight 
reduct ion 
a f te r cessat ion 
of the NSAID 
3.4 
6.9 
5.5 
2.3 
unknown 
Su rv i va l , 
years 
> 2 
> 4.5 
> 3 
> 3.5 
1 * * 
* assessed with the aid of a nomogran by the method of Siersbaek-Nielsen et a l . ' 
NSAID indicates nonsteroidal anti-inflammatory drugs 
**patient died of carcinoma of the pancreas 
CHAPTER Vili 
SUMMARY ANO CONCLUSIONS 
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SUMMARY AND CONCLUSIONS 
Non-steroidal anti-inflammatory drugs (NSAID) are the f i r s t choice in 
the symptomatic treatment of inflammatory j o i n t diseases. Disease-
associated changes in the function of body organs or in the 
composition of blood proteins, and individual patient characteristics 
alter drug disposit ion. The studies in th is thesis concerned in 
particular the pharmacokinetics of the NSAID naproxen in relat ion to 
age and disease a c t i v i t y in patients with rheumatoid a r t h r i t i s . 
Furthermore, a study was made of two adverse drug reactions both 
connected with the use of NSAID, either in the treatment of 
rheumatoid a r t h r i t i s or for j o i n t complaints in the aged patient. 
Chapter I describes the drug studied, naproxen, and the implications 
of f luctuations in disease act iv i ty in patients with rheumatoid 
a r t h r i t i s . 
Chapter I I gives the results of a pharmacokinetic study on eight 
patients with classic or def in i te rheumatoid a r t h r i t i s and active 
polyart icular i n f l anmation, studied during chronic treatment with 
500 mg naproxen twice dai ly in comparison with results in healthy 
young volunteers. 
The area under the concentration-time curve during one dose interval 
(AUC) of total naproxen was smaller in patients than in volunteers: 
64U101 mqh/l versus 896±85 mgh/1; ρ < 0.0001. This corresponds with 
a lower mean serum drug concentration in patients during one dose 
interva l . Protein-unbound drug concentrations were higher in 
patients, result ing in a larger (AUC)U than that of volunteers: 
1.9+0.9 mgh/1 versus 0.7+0.2 mgh/1; ρ < 0.01. 
Total body clearance and apparent volume of d i s t r i b u t i o n of the drug 
in patients increased in comparison with the volunteers. Naproxen 
elimination h a l f - l i f e did not change s i g n i f i c a n t l y . Volume of 
d i s t r i b u t i o n and clearance were inversely correlated with individual 
serum albumin concentrations. In contrast with total naproxen 
k inet ics, unbound clearance and volume of d i s t r i b u t i o n were smaller 
in patients. These differences in drug pharmacokinetics are discussed 
as result ing from mult iple causes: the age difference between 
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patients and volunteers, and the hypoalbumiηaemi a in patients 
(28t2 g/1 versus 45+2 g/1 in volunteers), associated with active 
rheumatoid arthritis or disease activity itself. 
To study age and disease activity as factors determining naproxen 
pharmacokinetics the studies presented in the next three chapters 
were performed. 
Chapter III describes the results of a pharmacokinetic study of 
naproxen 500 mg twice daily in six elderly patients (mean age 73t2.9 
years) in comparison with those in eight healthy young volunteers 
(mean age 24±2.5 years). In the elderly patients the AUC of total 
naproxen was smaller; total body clearance and volume of distribution 
were increased. Unbound naproxen (AUC) U was larger in the elderly 
as compared with the young, together with a decrease in unbound 
clearance of the drug. The pharmacokinetic differences between the 
aged and the young may be explained by a lower serum albumin 
concentration (34+5 g/1 versus 45t2 g/1 in the young), together with 
a decrenent in naproxen albumin binding affinity and a significant 
reduction in clearance of unbound drug in the elderly: 281+96 1/h 
versus 713+164 1/h; ρ < 0.001. The origin of the diminished binding 
affinity in the aged may be: either changes in the structure of the 
albumin molecule or the presence of endogenous inhibitors of binding. 
At this moment there is no clear answer to this question. Also one 
can only speculate about the nature of the diminished clearance of 
unbound naproxen in elderly patients. The advice to the clinician to 
start naproxen therapy in the aged at a low dosage and increase 
stepwise if necessary ("go low, go slow") is supported by the finding 
of higher free drug concentrations in the elderly. 
Chapters IV and V present the results of a within-patient study of 
naproxen pharmacokinetics, comparing a period of active polyarticular 
inflammation with a period of improvement. The patients were 
receiving chronic treatment with naproxen 500 mg twice daily. Total 
naproxen concentrations were significantly lower in active disease, 
together with a significantly larger volume of distribution and 
clearance. Peak unbound drug concentrations were 29+19% (ρ < 0.05) 
lower at the time of improvenent, but trough concentrations and 
concentrations of unbound drug measured in both periods after the 
dose interval up to60 hours were indistinguishable. The unbound 
naproxen clearance was snaller in the period of active disease: 
390±277 1/h in comparison with improvement: 488+343 1/h; ρ < 0.05. In 
some patients a difference in albumin binding a f f i n i t y existed; at 
th is moment we can give no f inal explanation of the cause of t h i s 
f ind ing, nor judge i t s c l i n i c a l implications. In any case disease 
a c t i v i t y in patients with rheumatoid a r t h r i t i s alters naproxen 
disposit ion. Hypoalbuminaemia associated with active polyarticular 
i n f l armation (mean serum albumin 30t4 g / 1 , versus 41±2 g/1 in 
improvement) explains a larger volume of d i s t r i b u t i o n and clearance 
of the drug. A calculat ion of the unbound naproxen pharmacokinetics 
revealed a decrement in clearance at the time of active disease, 
possibly as a consequence of reduced hepatic uptake from plasma or a 
hampered metabolism of the drug. 
The c l i n i c a l implications are: 
- a possible beneficial effect due to higher unbound naproxen 
concentrations in patients with active polyart icular inflanmation, 
assuming that unbound drug levels correlate with therapeutic 
e f f e c t ; and the other side of the coin: 
- a possible higher frequency of adverse drug reactions as a 
consequence of the higher unbound drug levels in patients with 
active disease. 
The rationale for the study described in Chapter VI , the assessment 
of gastrointestinal blood loss associated with NSAID treatment using 
51cr-labelled erythrocytes, was the observation of higher unbound 
naproxen concentrations in patients with active rheumatoid 
inflammation. In view of these higher unbound drug levels one might 
expect an increased pharmacological ef fect, and thus a relationship 
between the amount of gastrointestinal damage, measured as faecal 
51cr loss, and the unbound naproxen concentration in patients with 
active rheumatoid a r t h r i t i s . However, no signif icant correlation was 
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found, either with unbound or total drug concentrations, or duration 
of naproxen therapy, or degree of disease a c t i v i t y in individual 
patients. The results of faecal 51ο loss in our nine patients were 
quite simila'· to earl ier data on volunteers and out-patients with 
rheumatoid a r t h r i t i s . We concluded that i t was not useful to extend 
the number of part icipating patients or to compare the gastro­
intest inal 51çr loss in these patients with assessments in healthy 
volunteers taking naproxen. 
Furthermore, the follow-up of these patients after the study period 
i l l us t ra tes that absence of a more than expected 51ς
Γ
 i 0 S s has no 
predictive value for ulcerogenesis. 
Chapter VII describes observations on a suspected adverse drug 
reaction; i . e . congestive heart f a i l u r e due to NSAID treatment in the 
elderly. Twenty-two patients were reported by means of a question­
naire sent to 243 practicing physicians; 48% of the respondents 
expressed awareness of the p o s s i b i l i t y of congestive heart f a i l u r e as 
a NSAID-related side effect. In the University Hospital St Radboud, 
the medical records of 600 patients with congestive heart f a i l u r e 
revealed f i ve cases possibly attr ibutable to NSAID therapy. The 
probabi l i ty of an unwanted effect to be associated with the use of a 
drug, and thus to be an adverse drug reaction, can be assessed with 
standardized decision aids (algorithms). The nature of a r e t r o ­
spective study makes manoeuvres in individual patients impossible, 
and sometimes f i l e s are incomplete or important observations have not 
been made. Therefore, these algorithms f a i l to reach a high level of 
probabi l i ty in the described groups of patients. Our results confirm 
that congestive heart fa i lure does occur as an adverse drug reaction 
to NSAID therapy in the elderly. The incidence of this adverse drug 
reaction, or the ident i f icat ion of high-risk individuals, could not 
be derived from these data. 
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SAMENVATTING EN CONCLUSIES 
Niet-steroide anti-inflammatoire geneesmiddelen (NSAIO) z i j n de 
eerste keus b i j de symptomatische behandeling van gewrichts-
ontstekingen b i j ziekten van het bewegingsapparaat. Naast individu-
ele, patiëntgebonden eigenschappen, be'invloeden met ziekte samen-
hangende veranderingen in de functie van organen, of in de sanenstel-
l ing van bloedeiwitten de lotgevallen van een geneesmiddel in het 
lichaam. De onderzoekingen in d i t proefschri f t betroffen in het b i j -
zonder de farmacokinetiek van het NSAID naproxen in verband met leef-
t i j d en z iek te-ac t iv i te i t van patiënten met rheumatoide a r t h r i t i s . 
Verder werden twee bijwerkingen bestudeerd, die samenhangen met het 
gebruik van NSAID b i j de behandeling van rheumatoide a r th r i t i s of met 
het gebruik wegens gewrichtsklachten b i j bejaarde patiënten. 
Hoofdstuk I beschr i j f t het geneesmiddel naproxen en de betekenis van 
de wisselingen in z iek te-act iv i te i t b i j patiënten met rheumatoide 
a r t h r i t i s . 
Hoofdstuk I I toont de resultaten van een farmacokinetische studie 
verricht t i jdens chronische behandeling met tweemaal daags 500 mg 
naproxen b i j acht patiënten met klassieke of zekere rheumato'ide 
a r th r i t i s en een actieve gewrichtsontsteking in vergel i jk ing met 
gezonde jonge v r i j w i l l i g e r s . Het oppervlak onder de concentratie-
t i jdcurve t i jdens één dosisinterval (AUC) voor het totale naproxen 
bleek kleiner b i j patiënten dan b i j v r i j w i l l i g e r s : 641±101 mgh/1 
tegen 896+85 mgh/1; ρ < 0,0001. Dit behelsde dus een lager gemiddeld 
gehalte aan geneesmiddel in het serum ti jdens het dosisinterval b i j 
patiënten. Het niet-eiwitgebonden geneesmiddel-gehalte was hoger b i j 
de patiënten, met als gevolg een grotere (AUC)U dan die van 
v r i j w i l l i g e r s : 1,9+0,9 mgh/1 tegen 0,7+0,2 mgh/1; ρ < 0,01. De tota le 
lichaamsklaring en het schijnbaar verdelinqsvolurne van de stof was 
b i j patiënten toegenomen in vergel i jk ing met v r i j w i l l i g e r s . De 
eliminatie halfwaardetijd was niet s igni f icant verschil lend. Het 
verdelingsvolume en de klaring toonden een negatieve correlat ie met 
het individuele serum albumine-gehalte. In tegenstell ing to t de 
kinetiek voor het totale naproxen waren de v r i j e klaring en het ver-
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delingsvolume van de niet-eiwitgebonden stof kleiner b i j de patiën-
ten. Deze verschil len in fannacokinetiek l i j ken meerdere oorzaken te 
hebben, die in de discussie worden besproken: het verschil in leef-
t i j d tussen patiënten en v r i j w i l l i g e r s , de hypalbuminemie b i j patiën-
ten (28±2 g/l tegen 45Í2 g/l b i j v r i jw i l l i ge rs ) waarmee actieve 
rheumatoide a r t h r i t i s gepaard gaat, of de z iek te-act iv i te i t ze l f . 
Om lee f t i j d en z iek te-ac t iv i te i t als de bepalende factoren voor 
naproxen-kinetiek te bestuderen werden de onderzoekingen, die in de 
hierop volgende drie hoofdstukken zi jn uiteengezet, ondernomen. 
In Hoofdstuk I I I worden de resultaten beschreven van een fannaco-
kinetische studie met tweemaal daags 500 mg naproxen b i j zes bejaarde 
patiënten (gemiddelde l ee f t i j d 73t2,9 jaar) in vergeli jking met die 
van acht jonge gezonde v r i jw i l l i ge rs (gemiddelde l ee f t i j d 24t2,5 
jaa r ) . Bij de bejaarde patiënten was de AUC voor totaal naproxen 
kleiner, de totale lichaamsklaring en het verdelingsvolume waren 
groter. De niet-eiwitgebonden (AUC)U van naproxen was groter b i j de 
ouderen in vergel i jk ing met de jongeren, samen met een verminderde 
klaring van het v r i j e naproxen. De verschil len in farmacokinetiek 
tussen ouderen en jongeren kunnen worden verklaard ui t een lager 
serum albuminegehalte (34±5 g/l tegen 45+2 g/l b i j de jongeren), 
samen met een verminderde b indingsaf f in i te i t van naproxen aan 
albumine en een signi f icant kleinere klaring (281t96 l/h tegen 
713±164 l / h ; ρ < 0,001) van de v r i j e stof b i j de bejaarden. De 
verminderde b i n d i n g s a f f i n i t e i t b i j ouderen kan voortkomen u i t : ofwel 
veranderingen in de structuur van het albumine molecule, ofwel de 
aanwezigheid van lichaamseigen stoffen die de binding hinderen. Op 
d i t moment bestaat op deze vraag geen sluitend antwoord. Ook kan men 
slechts speculeren over de oorzaak van de verminderde klaring van 
niet-eiwitgebonden naproxen b i j oudere mensen. Het advies aan de 
kl inicus om naproxen-therapie b i j ouderen met een lage dosis te 
beginnen en de dosis stapsgewijze te verhogen wanneer nodig "go low, 
go slow", wordt door de bevinding van hogere v r i j e geneesmiddel­
concentraties b i j bejaarden gesteund. 
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In Hoofdstuk IV en Hoofdstuk V worden de resultaten getoond van een 
farmacokinetische studie, waarbij dezelfde patiënten met rheumatoide 
a r th r i t i s werden onderzocht t i jdens een periode van actieve 
gewrichtsontsteking en een periode van vermindering of afwezigheid 
hiervan. De patiënten gebruikten chronisch tweemaal daags 500 mg 
naproxen. Tijdens de actieve ziekte-periode waren de totale naproxen-
concentraties signi f icant lager, samen met een groter verdelings-
volume en klar ing. De hoogst gemeten niet-eiwitgebonden concentraties 
waren 29+19% lager (p < 0,05) op het moment dat de ziekte in een 
rustige fase verkeerde, maar de dalspiegels en de spiegels van het 
niet-eiwitgebonden naproxen die in beide perioden werden bepaald na 
het dosisinterval tot 60 uur waren niet van elkaar verschil lend. De 
klaring van niet-eiwitgebonden naproxen was kleiner t i jdens de 
actieve ziekteperiode: 390+277 l / h , in vergel i jk ing met de rustige 
periode: 488±343 l / h ; ρ < 0,05. Er bestond b i j enkele patiënten een 
veranderde bindingsact iv i te i t van naproxen aan albumine; hiervoor is 
geen goede verklaring voorhanden, evenmin er een oordeel over de 
klinische betekenis ervan kan worden gegeven. In ieder geval 
beïnvloedt de z iek te-ac t iv i te i t de lotgevallen van naproxen in het 
lichaam van de patiënt met rheumatoide a r t h r i t i s . De periode van 
actieve ziekte gaat gepaard met hypalbuminemie (serum albumine 
30+4 g/l tegen 41+2 g/l in de rustige periode), wat het grotere 
verdelingsvolume en klaring van naproxen verklaart. Berekening van de 
niet-eiwitgebonden farmacokinetiek van naproxen openbaarde een 
verminderde klaring ti jdens de actieve ziekteperiode, mogelijk als 
gevolg van een verminderde opname door de lever u i t het plasma of ten 
gevolge van een gestoord metabolisme van de stof . De klinische 
consequenties z i j n : 
- een mogelijk gunstig effect ten gevolge van hogere n ie t -e iw i t -
gebonden naproxen-concentraties, aangenomen dat deze correleren met 
het therapeutisch ef fect , b i j patiënten met actieve rheumatoide 
a r th r i t i s en 
- een mogelijk tevens grotere frequentie van bijwerkingen van het 
geneesmiddel, eveneens als gevolg van de hogere niet-eiwitgebonden 
concentratie b i j patiënten met actieve gewrichtsontsteking. 
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De achtergrond van het in Hoofdstuk VI beschreven onderzoek, de 
meting van gastrointestinaal bloedverlies ten gevolge van NSAID-
gebruik met behulp van 51cr-gelabeldé erythrocyten, was de bevin-
ding van de hogere niet-eiwitgebonden naproxen-concentraties b i j 
patiënten met actieve rheumatoide a r t h r i t i s . Men zou op grond van 
deze hogere v r i j e geneesmiddel-concentraties een krachtiger farmaco-
logisch effect kunnen verwachten, en dus een verband tussen de schade 
aan het maag-darmkanaal, gemeten als 51.Cr ver l ies , en de niet-
eiwitgebonden concentratie van naproxen b i j patiënten met actieve 
gewrichtsontsteking. Er werd echter geen signi f icant verband gevon-
den, noch met v r i j of totaal naproxen, noch met de duur van de 
naproxen-therapie, noch met de graad van z iek te-ac t iv i te i t b i j 
individuele patiënten. Het verl ies van 51çr b i j o n z e negen 
patiënten was geheel overeenkomstig met dat in studies verricht b i j 
v r i j w i l l i g e r s of niet in de kl iniek opgenomen patiënten met rheuma-
toide a r t h r i t i s . Wij concludeerden hierui t dat het niet zinvol was 
het aantal patiënten in de studie uit te breiden, of hun 51ο u i t ­
scheiding te vergelijken met metingen b i j v r i j w i l l i g e r s t i jdens 
naproxen-gebruik. Verder l i e t het vervolg van de patiënten na de 
studie zien, dat het ontbreken van een meer dan te verwachten faecaal 
51Cr ver l ies geen voorspellende waarde heeft voor het al dan niet 
ontstaan van een ulcus. 
Hoofdstuk VII beschr i j f t het onderzoek naar een vermoede bijwerking 
van NSAID b i j bejaarden, te weten decompensatio cordis. Uit een 
enquête verzonden naar 243 artsen verkregen we gegevens over 22 
patiënten b i j wie verdenking op de bijwerking bestond; van de respon-
denten meldde 48% op de hoogte te z i jn van de bijwerking decompen-
satio cordis ten gevolge van NSAID-therapie b i j bejaarden. 
In de medische dossiers van 600 patiënten met decompensatio cordis in 
het Sint Radboud Ziekenhuis werden 5 patiënten gevonden, waarvan de 
decompensatie mogelijk tot waarschijnli jk aan het gebruik van NSAID 
te wijten was. De waarschijnli jkheid waarmee een ongewenst effect 
samenhangt met het gebruik van een geneesmiddel, en derhalve een 
bijwerking i s , kan worden geschat met gebruikmaking van gestan-
% 
daardiseerde beslissingstabellen (algoritmen). De aard van een 
retrospectief onderzoek verhindert de uitvoering van onderzoek b i j de 
patiënt ze l f , soms bl i jken gegevens incompleet of z i jn belangrijke 
waarnemingen niet verr icht . In de beschreven patiëntengroepen komen 
de bijwerkingen-algoritmen j u i s t hierom niet tot een grote waar-
schi jn l i jkheid voor de vermoede bijwerking. De resultaten van het 
onderzoek bevestigen dat decompensatio cordis ten gevolge van het 
gebruik van NSAID b i j bejaarden voorkomt. Uit deze gegevens konden 
noch de incidentie van de bijwerking, noch de r isicofactoren b i j 
individuele patiënten hiervoor, worden afgeleid. 
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De omslag van het proefschrift werd verzorgd door G. Peeters van de 
afdeling Reprografie; hier werd ook het drukwerk v e r r i c h t . 
Voor secretariële werkzaamheden ben ik dank verschuldigd aan T. de 
Jong (Sarva Syntex Nederland, Ri jswi jk) , A. van Loon (Nucleaire 
Geneeskunde) en K.E. van Horssen-Hamerslag (Reumatologie). G.CA. 
Wessel-Hoogstraaten verzorgde met grote toewijding het merendeel van 
de manuscripten van de art ikelen, bracht de hoofdstukken van d i t 
proefschri f t op tekstverwerker, corrigeerde de tekst en verwerkte 
wijzigingen; gaf tenslotte de f inishing touch aan het geheel. 
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CURRICULUM VITAE 
De schrijver van d i t proefschrift werd op 28 september 1953 geboren 
te Nieuw-Ginneken. Hij behaalde in 1972 aan het Onze Lieve Vrouwe 
Lyceum te Breda het eindexamen Hogereburgerschool В en studeerde 
vervolgens Geneeskunde aan de Katholieke Universiteit te Nijmegen. 
Het doctoraal examen Geneeskunde werd afgelegd in 1977 en het arts­
examen in september 1979. 
Tijdens het vervullen van de m i l i t a i r e dienstpl icht werd h i j , na de 
basistraining, als reserve-eerste-luitenant-arts gedetacheerd b i j de 
afdeling Bloedziekten van het St Radboud Ziekenhuis te Nijmegen 
(hoofd: prof.dr С Haanen). Hij participeerde in onderzoek naar de 
ontwikkeling van methoden tot zuivering en preservatie van hemato-
poëtische progenitorcellen. 
In juni 1981 werd aangevangen met de opleiding tot internist in het 
St Radboud Ziekenhuis (opleider: prof.dr A. van ' t Laar), welke naar 
verwachting zal worden voltooid in september 1987. 
Van oktober 1984 to t apri l 1987 was h i j werkzaam binnen de werkgroep 
Klinische Farmacologie en Farmacokinetiek (hoofd: prof.dr F.W.J. 
Gribnau) van het Laboratorium Farmacologie (hoofd: prof.dr C.A.M, van 
Ginneken) en de onderafdeling Reumatologie (hoofd: prof.dr L.B.A. van 
de Putte) van de Kliniek voor Inwendige Ziekten van het St Radboud 
Ziekenhuis. In deze periode is het onderzoek verr icht dat de basis 
vormde voor d i t proefschr i f t . 
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STELLINGEN 
1. Bij een sterk eiwitgebonden geneesmiddel kan zich de 
paradoxale situatie voordoen, dat een toegenomen totale 
lichaamsklaring gepaard gaat met een verminderde plasma-
klaring van de niet-eiwitgebonden stof; dit resulteert 
in hogere niet-eiwitgebonden concentraties. 
dit proefschrift. 
2. Rheumatoide arthritis beinvloedt klaring en verdelings-
volume van totaal en niet-eiwitgebonden naproxen; dit 
resulteert bij patiënten met een hypoalbuminaemie ten 
gevolge van aktieve ziekte in lagere totale en hogere 
niet-eiwitgebonden serumconcentraties gedurende het 
dosisinterval. 
dit proefschrift. 
3. Het advies naproxen therapie bij bejaarde patiënten met 
een lage dosis aan te vangen en slechts zo nodig te ver-
hogen, vindt extra rechtvaardiging in de te verwachten 
hogere, niet-eiwitgebonden naproxen serumconcentraties. 
dit proefschrift. 
4. Bij patiënten met rheumatoide arthritis, die met naproxen 
worden behandeld, bestaat geen bewijs voor de veronder-
stelling als zou het verlies van radioaktiviteit met de 
faeces uit 5lCr-gelabelde erythrocyten gerelateerd zijn 
aan de serumspiegels van het geneesmiddel of de ziekte-
aktiviteit van rheumatoide arthritis. 
dit proefschrift. 
5. Het verdient overweging het waarnemen, duiden en vast-
leggen van bijwerkingen van geneesmiddelen op te nemen 
als onderwerp in het basisonderwijs interne geneeskunde; 
dit mede in het licht van het vrijwel ontbreken van mel-
dingen van bijwerkingen uit de academische klinieken. 
Meyboon R.H.B. Het »eitlen van bijwerkingen van geneesaiddelen in Nederland. 
Ned lijdschr Geneeskd 1986; 130: 1979-1683. 
Faich G.A. Adverse-drug-reaction nonitoring. 
Ne« Engl J Med 1986; 31Ί: 1589-1592. 
6. De r e g i s t r a t i e van geneesmiddelen moet periodiek worden 
getoetst aan de stand van de wetenschap; aanpassingen in 
de b i j s l u i t e r t e k s t zouden de voorschrijvende ar t s op 
duidelijke wijze kenbaar moeten worden gemaakt. 
Herxheimer A. Basic information that prescnbers are not getting about drugs. 
Lancet 1987; ι : 31-32. 
7. De klinisch-therapeutische beoordeling van geneesmiddelen 
voor r e g i s t r a t i e i s gebaat bij de inbreng van medici, die 
werkzaam zijn in de klinische prakti jk. 
8. Bij s tabiele inspanningsafhankelijke angina pector is , 
die onvoldoende reageert op continue transcutane n i t r o ­
glycerine toediening (Trasiderm-Nitro®), kan verlaging 
van de dosis per dag door intermitterende toediening 
zinvoller zijn dan het in de Nederlandse b i j s l u i t e r 
gegeven advies to t dosisverhoging. 
Cowan D., Bourke J . , Reíd D.S. & Julian В.G. Tolerance to glyceryl 
t r i n i t r a t e patches: prevention by intermittent dobing. 
Br Med J 198?; 29 ,i: S'i't-S'tS. 
9. De oogboldrukverlagende werking bij glaucoom door 
1-timolol maleaat (Timoptol®) berust niet op de 
S-blokkerende eigenschappen van di t middel. 
Keates E.U. i Stone R. The effect of d-timolol on intraocular pressure 
in patients with ocular hypertension. 
Am J Ophtalmol ^ Θ Ί ; 98: 73-78. 
Leopold Ι.Η к Duzman E. Observations on the pharmacology of glaucoma. 
Ann Rev Pharmacol Tomcol 1986; 26: ΊΟΙ-ΊΣβ. 
10. De conclusies van Abernathy et a l . aangaande de werking 
en kinetiek van d, 1-verapamil (Isoptin1 8) zijn van weinig 
waarde, daar geheel voerbij is gegaan aan het verschil 
in farmacologisch effect tussen beide stereoisomeren en 
het stereospecifiek metabolisme. 
Abernathy D.R., Schwarz J.B., Todd E.L., Luchi S. 1 Snow E. Verapamil 
pharmacodynamics and disposition in ч"
и
пд and elderly hypertensive patients. 
Ann Intern Med 1986; 105: 329 33b. 
Echizen H., Vogelge^'-y B. 1 Eichelbaum M. Effects of d,l-verapamil on 
atrioventncLldT conduction in relation to i ts stereoselective f i r s t -
pas': ETietabolism. 
Clin Pharmacol Ther 1985; 38: 71-76. 
11. Het is nuttig, bij de bestudering van het Medical 
Knowledge Sel f-Assessment Program van het American 
College of Physicians, in gedachten te houden, dat 
soms de gegeven antwoorden Noord-Amerikaanse ant-
woorden op Noord-Amerikaanse problemen zijn. 
12. In een enkel geval kan met één patient een "randomised 
clinical trial" worden uitgevoerd. 
McLeod U.S., Cohen Ζ., Taylor D.W. i lullen J.B. Single-patient 
randomised clinical trial. 
Lancet 1986; i: 726-728. 
13. Het als uniek voor het NSAID suprofen beschreven bij­
werkingensyndroom, bestaande uit een acute reversibele 
nierfunktiestoornis met Proteinurie en pijn in de flanken, 
lijkt zijn enigheid eerder te ontlenen aan de lijders 
(voornamelijk Noord-Amerikanen, werkzaam in de gezondheids 
zorg) dan aan de verschijnselen op zich. 
Hart D., Ward M. I Lifschitz M.D. Suprofen-related nephrotoicicity. 
Ann Intern Med 1987; 106: 235-238. 
14. Eén voordeel, voortvloeiend uit de door het Ministerie 
van WVC aangekondigde beëindiging van de gratis toezending 
van het "Geneesmiddelenbulletin", is de nu verworven 
zekere kennis dat 6000 artsen in Nederland bereid zijn 
financieel bij te dragen in hun onafhankelijke genees-
middelen informatie. 
Een opiniepeiler zou tegen aanzienlijke kosten een veel 
minder betrouwbaar antwoord op deze vraag hebben kunnen 
geven. 
Nijmegen, 22 mei 1987 Frank van den Ouweland. 



